



(19)

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 201 765 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
02.05.2002 Bulletin 2002/18

(51) Int Cl.7: C12Q 1/48, C07K 16/00,
A61P 31/12, A61K 39/395,
A61K 48/00, C12Q 1/68

(21) Application number: 01124604.8

(22) Date of filing: 15.10.2001

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU

MC NL PT SE TR

Designated Extension States:

AL LT LV MK RO SI

(30) Priority: 16.10.2000 US 240750 P

(71) Applicant: Axxima Pharmaceuticals
Aktiengesellschaft
82152 Martinsried (DE)

(72) Inventors:

- Schubart, Daniel
79576 Weil am Rhein (DE)
- Habenberger, Peter
81373 Munich (DE)

- Stein-Gerlach, Matthias
81475 Munich (DE)
- Bevec, Dorian
82110 Germering (DE)

(74) Representative: Leidescher, Thomas et al
Zimmermann & Partner,
Postfach 33 09 20
80069 München (DE)

Remarks:


The sequence listing, which is published as annex to the application documents, was filed after the date of filing. The applicant has declared that it does not include matter which goes beyond the content of the application as filed.

(54) Cellular kinases involved in cytomegalovirus infection and their inhibition

(57) The role of certain cellular kinases active during Human Cytomegalovirus infection is disclosed. These cellular kinases are useful to detect HCMV infection,

and can be used to screen for cellular kinase inhibitors. Cellular kinases inhibitors, which effectively downregulate these key cellular components, serve as effective therapeutics against HCMV infection.

Fig. 1



Description

[0001] The present invention is in the fields of molecular biology and virology. The present invention is directed to novel methods for treating Cytomegalovirus using kinase inhibitors.

5

Background of the Invention

[0002] Human Cytomegalovirus (HCMV) is a highly specific β -herpesvirus. Primary infection of healthy children and adults is usually asymptomatic, with a minority of cases developing a mononucleose-like syndrome. In contrast, congenital infection (U.S. 0.2%-2.2% per live birth; approx. 40,000 per year) leads to several neurological defects in 10-15% of infected neonates. Immunocompromised patients represent another host group facing serious disease complications caused by HCMV infection or reactivation of a persistent infection. Up to 40% of the AIDS patients, for example, develop retinitis, pneumonitis, gastroenteritis or disseminated HCMV disease. In addition, allograft recipients (20,000 allograft transplantations per year in the U.S.) are often infected (or superinfected) by virus from the transplanted organ.

10

[0003] Clinical symptoms in the posttransplant period include prolonged fever, leukopenia, thrombocytopenia, atypical lymphocytosis, elevated hepatic transaminases and decreased graft survival. In bone marrow transplantations, HCMV infection is associated with high mortality rates (80-90% for untreated HCMV pneumonia).

15

[0004] Current approaches to develop therapeutics against Cytomegalovirus (CMV) have focused on antiviral agents *per se*; for example viral polymerase inhibitors. In fact, high mortality rates have been dramatically reduced by new antiviral agents. Current CMV therapeutics possess severe drawbacks, however. For example, Fomivirsen (Vitravene, formerly ISIS 2922) is typically administered by injection directly into the eye every 2 or 4 weeks. Ganciclovir is available for intravenous (Cytovene) or oral administration, and as an implant in the case of retinitis; unfortunately, toxic complications including leukopenia and thrombocytopenia frequently develop. Foscarnet (Foscavir; phosphonoformic acid), another antiviral agent, exhibits considerable renal toxicities and is only available in intravenous form (which is also true for Cidofovir (Vistide), another CMV therapeutic). In addition, CMV replication resumes soon after Ganciclovir and Foscarnet treatment is halted. Finally, Ganciclovir- and Foscarnet-resistant strains of CMV are emerging.

20

[0005] Although treatment of HCMV-induced disease has been improved with these inhibitors of the viral polymerase and preemptive or early antiviral therapy in transplant patients, there is a need in the art for a new class of HCMV therapeutics with better oral bioavailability and reduced toxic effects. This is especially true in the treatment of retinitis in AIDS patients, where CMV infection must be controlled for long periods of time.

25

[0006] Recent research has revealed how cells communicate with each other to coordinate the growth and maintenance of the multitude of tissues within the human body. A key element of this communication network is the transmission of a signal from the exterior of a cell to its nucleus, which results in the activation or suppression of specific genes. This process is called signal transduction.

30

[0007] An integral part of signal transduction is the interaction of cytokines, their receptors, and intracellular signal transduction molecules. Cytokines serve as messengers that bind to receptors on the surface of a target cell. As a result of the binding, the receptors activate a cascade of downstream signaling molecules, thereby transmitting the message from the exterior of the cell to its nucleus. Signal transduction to the nucleus modulates specific gene expression (i.e., transcription and translation), which results in either the upregulation or downregulation of specific proteins that carry out a particular biological function.

35

[0008] Viral infection disrupts normal signal transduction, which leads to cellular malfunctioning resulting in a disease state. Specifically, interference of HCMV with relevant human primary cells is necessary for the virus to create an environment that allows it to grow and replicate, and in turn cause disease in the infected individual. Current research efforts have failed to elucidate all the specific intracellular signal pathways affected by HCMV infection, however. Discovery of the signal transduction pathways and specific intracellular signal transduction molecules affected by CMV infection would represent a tremendous advance in the understanding of the induction and progression of CMV infection processes and provide new avenues for the development of a novel class of effective therapeutics for the treatment of CMV.

40

[0009] Thus, object of the present invention is to provide methods for detecting, preventing and/or treating Cytomegalovirus infection and/or associated diseases, methods for the identification of compounds useful for preventing and/or treating Cytomegalovirus infection and/or associated diseases and for regulating the production of Cytomegaloviruses.

45

[0010] The object of the present invention is solved by the teaching of the independent claims. Further advantageous features, aspects and details of the invention are evident from the dependent claims, the description, and the examples of the present application.

Description of the invention

[0011] The present invention is based upon the finding of a group of cellular kinases that are specifically upregulated as a result of CMV infection. The antiviral therapeutic research approach described herein, focuses on discovering the cellular signal transduction pathways involved in viral infection. Identification of the cellular signal transduction molecules, key to viral infection provides for, among other things, novel diagnostic methods, especially assays, and compositions useful therefor, novel targets for antiviral therapeutics, a novel class of antiviral therapeutics, and new screening assays and materials to discover new antiviral agents.

[0012] This approach led to the development of a novel microarray platform technology, wherein a microarray of more than 1100 signal transduction cDNAs was developed. This unique microarray technology was used to identify RNA expression patterns (e.g., upregulation or downregulation) unique to CMV infected host cells. Differential display techniques were used to pinpoint those signal transduction molecules useful as targets for drug intervention. Effective manipulation of these virally-controlled intracellular signal transduction pathways can alter (slow or stop altogether) the course of viral growth.

[0013] It is now revealed for the first time that the cellular protein kinases RICK (also known as CARDIAK; RIP2), RIP, NIK (also known as HGK; MAP4K4), MKK3 (also known as MEK3), and SRPK-2 are specifically and uniquely upregulated in a cell as a result of CMV infection. These cellular kinases therefore identify novel diagnostic and therapeutic targets for CMV infection.

[0014] Surprisingly, it was found that the following human cellular targets are significantly upregulated compared with uninfected human foreskin fibroblasts cells:

| target | upregulation |
|--------|--------------|
| RICK | 3.6 fold |
| RIP | 2.6 fold |
| NIK | 4.0 fold |
| MKK3 | 2.5 fold |
| SRPK-2 | 2.2 fold |

[0015] Based upon the research work reported herein, one aspect of the present invention is directed to a method, preferably a screening assay, for identifying compounds useful for treating and/or preventing Cytomegalovirus infection and/or diseases associated therewith. Specifically, this assay involves contacting a test compound with one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2, and detecting a change, normally a decrease, in activity of said cellular kinase. This method was used for the identification of the RICK and RIP inhibitors shown below in Table 1 and Table 2.

[0016] Another aspect of the invention is directed to a diagnostic method for detecting Cytomegalovirus infection and/or associated diseases in an individual or in cells and/or in cell lysates. This assay involves providing a sample from the individual or providing a sample from said cells, respectively, and detecting activity of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2. The term "individual" preferably refers to mammals, especially humans or ruminants.

[0017] Also described in the present invention are monoclonal or polyclonal antibodies which bind to a cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

[0018] A further aspect of the present invention relates to a method for preventing and/or treating Cytomegalovirus infection and/or associated diseases in an individual by administering a pharmaceutically effective amount of an inhibitor to said individual, wherein said inhibitor inhibits at least partially the activity of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2, or wherein said inhibitor inhibits at least partially the production of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

[0019] As used herein, the term "inhibitor" refers to any compound capable of downregulating, decreasing, reducing, suppressing or inactivating the amount and/or activity of at least one human cellular protein kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2. Generally, said inhibitors, including suicide inhibitors, may be proteins, oligo- and polypeptides, nucleic acids, genes, small chemical molecules, or other chemical moieties. Suitable inhibitors are monoclonal or polyclonal antibodies which bind to at least one cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

[0020] Based on the surprising results reported herein, one aspect of the present invention is directed to a method for regulating the production of Cytomegalovirus in an individual by administering an individual a pharmaceutically effective amount of an inhibitor wherein said inhibitor inhibits at least partially the activity of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2, or wherein said inhibitor at least partially

inhibits the production of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

[0021] A similar aspect relates to a method for regulating the production of Cytomegalovirus in cells by administering the cells a pharmaceutically effective amount of an inhibitor wherein said inhibitor inhibits at least partially the activity of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2, or wherein said inhibitor at least partially inhibits the production of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2 in the cells.

[0022] Yet another aspect of the invention is directed to a method for regulating the expression of at least one cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2 in an individual comprising the step of administering the individual a pharmaceutically effective amount of an inhibitor wherein said inhibitor inhibits at least partially the transcription of DNA or the translation of RNA encoding one of said cellular kinases.

[0023] A further aspect relates to a method for regulating the expression of at least one cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2 in the cells comprising the step of administering the cells a pharmaceutically effective amount of an inhibitor wherein said inhibitor inhibits at least partially the transcription of DNA or the translation of RNA encoding one of said cellular kinases.

[0024] As used herein, the term "regulating expression and/or activity" generally refers to any process that functions to control or modulate the quantity or activity (functionality) of a cellular component. Static regulation maintains expression and/or activity at some given level. Upregulation refers to a relative increase in expression and/or activity. Accordingly downregulation refers to a relative decrease in expression and/or activity. In the present invention, regulation is preferably the downregulation of a cellular component. Downregulation is synonymous with inhibition of a given cellular component's activity.

[0025] Beside inhibitors also activators may be useful for treating Cytomegalovirus infection by increasing the activity of at least one of the cellular protein kinases RICK, RIP, NIK, MKK3, and SRPK-2. Thus, a method for preventing and/or treating Cytomegalovirus infection and/or associated diseases in an individual is disclosed. Said method comprises administering a pharmaceutically effective amount of an activator to an individual, wherein said activator activates at least partially the activity of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2, or wherein said activator activates or stimulates at least partially the production of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

[0026] Furthermore, a method for regulating the production of Cytomegalovirus either in cells or in an individual is described. Said methods comprise administering an individual or to cells a pharmaceutically effective amount of an activator wherein said activator activates at least partially the activity of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2, or wherein said activator at least partially activates or stimulates the production of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

[0027] As used herein, the term "activator" refers to any chemical compound which is able to upregulate, increase, activate, or stimulate the activity of at least one human cellular protein kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2 or which is able to upregulate, increase, activate, or stimulate the expression of at least one of said cellular kinases. Activators comprise proteins, oligo- and polypeptides, nucleic acids, genes, and preferably small chemical molecules, or other chemical moieties.

[0028] Still another aspect of the present invention is directed to either a method for regulating the expression of at least one cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2 in an individual or for regulating the expression of at least one of said kinases in cells. These methods comprise the step of administering the individual or the cells a pharmaceutically effective amount of an activator wherein said activator activates at least partially the transcription of DNA or the translation of RNA encoding one of said cellular kinases.

[0029] Furthermore, oligonucleotides are disclosed which bind to the DNA or RNA encoding a cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2. Said oligonucleotides can be used as suitable inhibitors within the aforementioned methods.

[0030] Some methods of the present invention identify compounds useful for prophylaxis and/or treatment of Cytomegalovirus infection and/or associated disease by screening a test compound, or a library of test compounds, for its ability to inhibit at least one of the above-mentioned human cellular protein kinases identified herein as characteristically upregulated during HCMV replication. Using this method the compounds A to E have been identified as RICK inhibitors and the compounds F to H have been identified as RIP inhibitors. Thus, the use of these compounds as inhibitors of RICK or RIP is disclosed. Furthermore, these compounds can be used for manufacturing a pharmaceutical composition for prophylaxis and/or treatment of Cytomegalovirus infection and/or diseases associated with Cytomegalovirus infection.

[0031] A variety of assay protocols and detection techniques are well known in the art and easily adapted for this purpose by a skilled practitioner. Such methods include, but are not limited to, high throughput assays (e.g., microarray technology, phage display technology), and *in vitro* and *in vivo* cellular and tissue assays.

[0032] Thus, some embodiments of the present invention may comprise a solid support useful for detecting Cytomegalovirus infection in a cell or an individual. Preferably the solid support comprises immobilized oligonucleotides, wherein the oligonucleotides are capable of detecting activity of one or more cellular kinases selected from the group consisting of: RICK, RIP, NIK, MKK3, and SRPK-2.

5 [0033] Another aspect of the invention includes a solid support useful for screening compounds useful for treating Cytomegalovirus. Preferred embodiments include a solid support comprising one or more immobilized oligonucleotides, wherein the oligonucleotide(s) encode one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2. In another preferred embodiment, the solid support comprises one or more immobilized cellular kinases selected from the group consisting of: RICK, RIP, NIK, MKK3, and SRPK-2.

10 [0034] Accordingly, another aspect of the present invention is directed to a novel therapeutic composition useful to treat an individual afflicted with Cytomegalovirus comprising one or more inhibitors capable of inhibiting activity of one or more of the cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2. In addition thereto, a novel pharmaceutical composition could comprise at least one inhibitor capable of regulating the production 15 of HCMV by inhibiting the expression of at least one cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

[0035] Another group of suitable therapeutic compositions useful for prophylaxis and/or treatment of CMV comprises at least one activator which is able to increase the activity of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2 or which is capable of increasing the expression of at least one cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

20 [0036] Said pharmaceutical compositions may further comprise pharmaceutically acceptable carriers, excipient, diluents, fillers, binders, disintegrants, lubricants, glidants, coloring agents, flavoring agents, opaquing agents, and/or plasticizers.

Detailed description of the invention

25 [0037] Utilizing microarray technology, a unique microarray of more than 1100 signal transduction cDNAs was developed. This array was used to compare signal transduction mRNA expression patterns (e.g., upregulation or down-regulation) in primary human cells before and after infection with HCMV at various timepoints of infection. Interference of the HCMV with the cellular signaling events is reflected in differential gene expression when compared to the uninfected cellular signaling. Results from this novel signal transduction microarray analysis revealed significant upregulation of cellular protein kinases RICK, RIP, NIK, MKK3, and SRPK-2, as unique to CMV infected host cells. These findings were confirmed utilizing conventional Northern and Western blot analyses.

30 [0038] Disclosed herein is the first report describing the role of cellular kinases; RICK, RIP, NIK, MKK3, and SRPK-2 in the signal transduction of CMV viral infection process. As a result of these discoveries, a novel class of compounds, i.e., RICK, RIP, NIK, MKK3, and SRPK-2 inhibitors, are identified as useful for altering the course of CMV infection.

35 [0039] To perform initial tests for compounds that inhibit RICK activity in a cellular assay, RICK was transiently over-expressed in HEK-293 cells, immunoprecipitated and incubated with different concentrations of test compounds before in-vitro kinase assays were performed (Example 10). According to the method for identifying compounds useful for inhibiting the cellular kinase RICK and therefore useful for treating and/or preventing Cytomegalovirus infection and/or diseases associated with Cytomegalovirus infection, a test compound is contacted with the cellular kinase RICK according to the RICK assay protocol disclosed in example 10. The test compound dissolved in DMSO is added to the RICK assay solution at concentrations between 100 nM and 50 μ M. Thereafter, radioactively labeled ATP is added and kinase activity of RICK is determined by detecting the autophosphorylation of RICK via radioactivity measurement. The five compounds listed in the following Table 1 were identified using said method. These compounds showed 40 inhibition of RICK kinase activity with an IC₅₀ between about 500 nM and 1 μ M and an inhibition of HCMV with an IC₅₀ between about 1 and 8 μ M, respectively. The IC₅₀ values of HCMV inhibition were obtained by the use of at least one assay protocol selected from a) virus replication assay, b) plaque assay, c) GFP (Green Fluorescent Protein) infection assay, and d) indirect immunofluorescence analysis as disclosed in example 12. Thus, the five compounds A to E mentioned below and/or pharmaceutically acceptable salts thereof can be used as inhibitors of the cellular protein kinase RICK and as pharmaceutically active compounds for the treatment and/or prophylaxis of HCMV infection. Furthermore, these compounds are suitable for the manufacture of a pharmaceutical composition for prophylaxis and/or treatment of Cytomegalovirus infection and/or diseases associated therewith.

Table 1: Inhibitors of RICK and HCMV

| compound | structure | IC ₅₀ RICK | IC ₅₀ HCMV |
|----------------|-----------|-----------------------|-----------------------|
| 5 A | | 1 μ M | 6.8 μ M |
| 10 B | | 500 nM | 1.4 μ M |
| 15 30 35 | | 1 μ M | 6.2 μ M |

40

45

50

55

| | | | |
|----|--|--------|--------|
| 5 | | 500 nM | 7.6 µM |
| 10 | | 500 nM | 5.7 µM |
| 15 | | | |
| 20 | | | |

25

[0040] The compounds A to E have the following names:

Compound A: 6-(2,6-Dichlorophenyl)-8-methyl-2-(3-morpholin-4-yl-propylamino)-8H-pyrido[2,3-d]pyrimidin-7-one;
 Compound B: 8-methyl-6-phenyl-2-(pyridin-4-yl-amino)-8H-pyrido[2,3-d]pyrimidin-7-one;
 30 Compound C: 6-(2,6-Dichlorophenyl)-8-methyl-2-[3-(4-methylpiperazin-1-yl)-propylamino]-8H-pyrido[2,3-d]pyrimidin-7-one;
 Compound D: (3-Bromophenyl)-(6,7-diethoxyquinazolin-4-yl)-amine;
 Compound E: (3-Bromophenyl)-(6,7-dimethoxyquinazolin-4-yl)-amine.

35 [0041] From the results observed with the compounds shown in Table 1 it is proved that RICK is an important target for the treatment of HCMV and diseases associated with HCMV infection. Inhibitors of the human cellular protein kinase RICK may serve as new pharmaceutical substances for prophylaxis and/or treatment of Cytomegalovirus infection and/or diseases associated with CMV infection.

40 [0042] In addition to the chemical validation of RICK described above, a genetic validation of RICK in HCMV infection was performed. Wildtype and mutated RICK was expressed in HFF cells with a modified Adenovirus as vehicle (Example 9). The expression of both, wildtype and mutated RICK, caused a dramatic reduction in HCMV replication (cf. Fig. 2). Also these data confirm RICK as a valuable therapeutic target in HCMV treatment. As known in the art and as used herein, "RICK" refers to a protein kinase also known as "CARDIAK" and as "RIP2" which is a RIP-like kinase. RICK is essentially characterized as comprising an N-terminal serine-threonine kinase catalytic domain and a C-terminal region containing a caspase-recruitment domain (referred to as "CARD").

45 [0043] To perform initial tests for compounds that inhibit RIP activity in a cellular assay, RIP was transiently overexpressed in HEK-293 cells, immunoprecipitated and incubated with different concentrations of test compounds before in-vitro kinase assays were performed (Example 11). In order to identify compounds suitable for inhibiting the cellular kinase RIP and, thus, suitable for treating and/or preventing Cytomegalovirus infection and/or diseases associated with Cytomegalovirus infection the inventive method according to claim 1 was used. A test compound was contacted with the cellular kinase RIP according to the RIP assay protocol disclosed in example 11. The test compound dissolved in DMSO is added to the RIP assay solution at concentrations between 100 nM and 50 µM. Radioactively labeled ATP was used as co-substrate of RIP and auto-phosphorylation was detected via measurement of incorporation of radioactivity into the RIP protein. Thereafter, phosphorylation rates with and without test compounds were compared. The three compounds listed in the following Table 2 showed inhibition of RIP kinase activity with an IC_{50} between about 5 µM and 10 µM and an inhibition of HCMV with an IC_{50} between about 12 µM and 15 µM, respectively. The IC_{50} values of HCMV inhibition were obtained by the use of at least one assay protocol selected from a) virus replication assay, b) plaque assay, c) GFP infection assay, and d) indirect immunofluorescence analysis as disclosed in example 12.

[0044] Thus, the three compounds F to H mentioned below and/or pharmaceutically acceptable salts thereof can be used as inhibitors of the cellular protein kinase RIP and as pharmaceutically active compounds for the treatment and/or prophylaxis of HCMV infection. Furthermore, these compounds are suitable for the manufacture of a pharmaceutical composition for prophylaxis and/or treatment of Cytomegalovirus infection and/or diseases associated therewith.

5

Table 2: Inhibitors of RIP and HCMV

| compound | structure | IC ₅₀ RIP | IC ₅₀ HCMV |
|----------|-----------|----------------------|-----------------------|
| | | 5 µM | 15 µM |
| G | | 10 µM | 15 µM |
| H | | 5 µM | 12 µM |

40

[0045] The compounds F to H have the following names:

Compound F: 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one;

Compound G: 5-Cloro-3-(1H-pyrrol-2-ylmethylene)-1,3-dihydroindol-2-one;

45

Compound H: 4-Quinolin-4-ylmethylene-4H-isoquinoline-1,3-dione.

50

[0046] From the results observed with the compounds shown in Table 2 it is proved that RIP is an important target for the treatment of HCMV and diseases associated with HCMV infection. Inhibitors of the human cellular protein kinase RIP may serve as new pharmaceutical substances for prophylaxis and/or treatment of Cytomegalovirus infection and/or diseases associated with CMV infection.

[0047] In addition to the chemical validation of RIP described above, a genetic validation of RIP in HCMV infection was performed. Wildtype and mutated RIP was expressed in HFF cells with a modified Adenovirus as vehicle (Example 9). The expression of mutated RICK, but not wildtype RIP, caused a dramatic reduction in HCMV replication (cf. Fig. 1). These data also confirm RIP as therapeutic target in HCMV treatment.

55

[0048] As known in the art and as used herein, "NIK" (Nck-Interacting Kinase; also known as "HGK" or "MAP4K4") refers to an NF- κ B inducing serine/threonine kinase that interacts with the SH3 domains of Nck (an adaptor protein composed of one SH2 and three SH3 domains, known as a common target for a variety of cell surface receptors). NIK is most homologous to the Sterile 20 (Ste20) family of protein kinases, particularly GCK and MSST1 in that they bind

neither Cdc42 nor Rac and contain an N-terminal kinase domain with a putative C-terminal regulatory domain. NIK is reported to promote neurite process formation and mediated anti-apoptotic signaling. NIK expression leads to IKK activation and induced nuclear translocation of NF-kappaB. NIK activates MEK1 phosphorylation and induces the Erk1/Erk2 MAPK pathway. NIK has been shown to be a MEK1-dependent activator of the MAPK pathway (Foehr et al., 2000. *J. Biol. Chem.* 275, 34021-34024). Overexpression of NIK has been reported to specifically activate the stress-activated protein kinase (SAPK) pathway; possibly upstream of MEKK1, a dominant-negative MEK kinase 1 capable of blocking NIK activation of SAPK (Su et al., 1997. *EMBO* 16(6):1279-90).

[0049] As known in the art and as used herein, "MKK3" (MAP kinase kinase 3; also known as "MEK3") refers to a protein kinase known to function in TNF-induced cytokine expression, and specifically phosphorylate and activate p38 MAP kinase (Blank et al., 1996. *J. Biol. Chem.* 271:5361-5368; Raingeaud et al., 1996. *Mol. Cell. Biol.* 16(3):1247-55). MKK3 gene disruption has been shown to cause a selective defect in the response of fibroblasts to the proinflammatory cytokine tumor necrosis factor, including reduced p38 MAP kinase activation and cytokine expression; suggesting that the MKK3 protein kinase is a critical component of a tumor necrosis factor-stimulated signaling pathway that causes increased expression of inflammatory cytokines (Wysk et al., 1999. *PNAS USA* 96(7):3763-8).

[0050] As known in the art and as used herein, "SRPK-2" (SR-protein-specific kinase 2) refers to a kinase known to phosphorylate SF2/ASF and believed to regulate the disassembly of the SR family of splicing factors in a tissue-specific manner (e.g., in testis, lung, and brain; Kuroyanagi et al., 1998. *Biochem. Biophys. Res. Commun.* 242(2):357-64). SRPK-2 is believed to function in spliceosome assembly and in mediating the trafficking of splicing factors (Wang et al., 1998. *J. Cell. Biol.* 140(4):737-50; Wang et al., 1999. *Genomics* 57(2):310-5).

[0051] In one embodiment, the present invention is directed to a method for treating CMV infection by administering a pharmaceutically effective amount of an inhibitor of one or more of the cellular kinases; RICK, RIP, NIK, MKK3, and/or SRPK-2.

[0052] As used herein, a cellular kinase "inhibitor" refers to any compound capable of downregulating, decreasing, suppressing or otherwise regulating the amount and/or activity of a cellular kinase. Inhibition of these cellular kinases can be achieved by any of a variety of mechanisms known in the art, including, but not limited to binding directly to the cellular kinase polypeptide (e.g., a RICK-inhibitor compound binding complex, or substrate mimetic), denaturing or otherwise inactivating the cellular kinase, or inhibiting the expression of the gene (e.g., transcription to mRNA, translation to a nascent polypeptide, and/or final polypeptide modifications to a mature protein), which encodes the cellular kinase. Generally, cellular kinase inhibitors may be proteins, polypeptides, nucleic acids, small molecules, or other chemical moieties.

[0053] Yet another aspect of the present invention is directed to pharmaceutical compositions useful for the prophylaxis and/or treatment of an individual afflicted with Cytomegalovirus infection and/or associated diseases. Said pharmaceutical composition comprises at least one pharmaceutically active compound capable of regulating at least partially the activity or the expression of one human cellular protein kinase selected from the group comprising RICK, RIP, NIK, MKK3, and SRPK-2 and/or capable of regulating the replication of CMV.

[0054] As used herein the term "regulating" refers either to the ability of an inhibitor to downregulate, decrease, reduce, suppress, inactivate, or inhibit at least partially the activity of an enzyme, or the expression of an enzyme and the virus replication or to the ability of an activator to upregulate, increase, stimulate, or activate at least partially the activity of an enzyme or the expression of an enzyme.

[0055] Suitable examples for inhibitors which are the pharmaceutically active components within the therapeutic compositions are the compounds A to H mentioned in Table 1 and 2. The compounds 6-(2,6-Dichlorophenyl)-8-methyl-2-(3-morpholin-4-yl-propylamino)-8H-pyrido[2,3-d]pyrimidin-7-one; 8-methyl-6-phenyl-2-(pyridin-4-yl-amino)-8H-pyrido[2,3-d]pyrimidin-7-one; 6-(2,6-Dichlorophenyl)-8-methyl-2-[3-(4-methylpiperazin-1-yl)-propylamino]-8H-pyrido[2,3-d]pyrimidin-7-one; (3-Bromophenyl)-(6,7-dimethoxyquinazolin-4-yl)-amine; (3-Bromophenyl)-(6,7-diethoxyquinazolin-4-yl)-amine; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one; 5-Cloro-3-(1H-pyrrol-2-ylmethylene)-1,3-dihydroindol-2-one; 4-Quinolin-4-ylmethylene-4H-isoquinoline-1,3-dione and/or pharmaceutically acceptable salts of these compounds are useful for prophylaxis and/or treatment of Cytomegalovirus infection and/or diseases associated with Cytomegalovirus infection.

[0056] CMV therapeutics may be administered to cells from an individual *in vitro*, or may involve *in vivo* administration to the individual. Routes of administration of pharmaceutical preparations to an individual may include inhalation, oral and parenteral, including dermal, intradermal, intragastral, intracutane, intravasal, intravenous, intramuscular, intraperitoneal, intranasal, intravaginal, intrabuccal, percutan, rectal, subcutane, sublingual, topical or transdermal application, but are not limited the these ways of administration. For instance, the preferred preparations are in administratable form which is suitable for oral application. These administratable forms, for example, include pills, tablets, film tablets, coated tablets, capsules, powders and deposits. Administration to an individual may be in a single dose or in repeated administrations, and may be in any of a variety of physiologically acceptable salt forms, and/or with an acceptable pharmaceutical carrier, binder, lubricant, excipient, diluents and/or adjuvant. Pharmaceutically acceptable salt forms and standard pharmaceutical formulation techniques are well known to persons skilled in the art (see, for

example, Remington's Pharmaceutical Sciences, Mack Publishing Co.).

[0057] As used herein, a "pharmaceutically effective amount" of a cellular kinase inhibitor is an amount effective to achieve the desired physiological result, either in cells treated *in vitro* or in a subject treated *in vivo*. Specifically, a pharmaceutically effective amount is an amount sufficient to inhibit, for some period of time, one or more of the clinically defined pathological processes associated with the viral infection. The effective amount may vary depending on the specific kinase inhibitor selected, and is also dependent on a variety of factors and conditions related to the subject to be treated and the severity of the infection. For example, if the inhibitor is to be administered *in vivo*, factors such as the age, weight and health of the patient as well as dose response curves and toxicity data obtained in preclinical animal work would be among those considered. If the inhibitor is to be contacted with the cells *in vitro*, one would also

5 design a variety of pre-clinical *in vitro* studies to assess such parameters as uptake, half-life, dose, toxicity, etc. The determination of a pharmaceutically effective amount for a given agent is well within the ability of those skilled in the art.

[0058] As a result of the discovery of the upregulation of certain cellular kinases as part of the infection process of CMV, a novel diagnostic assay useful for the detecting CMV infection of an individual (or cell) is identified. The diagnostic assay of the present invention involves providing a sample from an individual or providing cells and/or cell lysates, and 10 detecting activity in the sample of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2. In one embodiment, deviations in the expression levels of one or more of the identified cellular kinases in a test sample compared to a known normal expression levels (e.g., determined from a sample from a healthy individual) will be diagnostic of CMV.

[0059] It is apparent to a practitioner in the art that a sample useful for detecting CMV infection, whether of a subject 20 individual or an isolated cell, refers to any cellular extract (including whole cells) from a tissue or body fluid (in the case of an individual) or cellular lysate (in the case of an isolated cell), which contains cellular components representative of cellular activity of one or more of the above-mentioned cellular kinases.

[0060] It is also apparent to a person of ordinary skill in the art that detection includes any method known in the art 25 useful to indicate the presence, absence, or amount of a detection target. Such methods may include, but are not limited to, any molecular or cellular techniques, used singularly or in combination, including, but not limited to: hybridization and/or binding techniques, including blotting techniques and immunoassays; labeling techniques (chemiluminescent, colorimetric, fluorescent, radioisotopic); spectroscopic techniques; separations technology, including precipitations, electrophoresis, chromatography, centrifugation, ultrafiltration, cell sorting; and enzymatic manipulations (e.g., digestion).

[0061] Because the present disclosure teaches for the first time the upregulation of a group of cellular kinases specifically involved in the viral infection of CMV, the present invention is also directed to an assay useful for detecting 30 novel compounds useful for treating CMV infection.

[0062] Assays of the present invention identify compounds useful for treating CMV operate by screening a test compound, or library of test compounds, for its ability to inhibit any one or more of the group of cellular kinases identified 35 herein as characteristically upregulated during CMV growth and replication inside a cell. A variety of assay protocols and detection techniques are well known in the art and easily adapted for this purpose by a skilled practitioner. Such assays include, but are not limited to, high throughput assays (e.g., microarray technology, phage display technology), and *in vitro* and *in vivo* cellular and tissue assays.

[0063] In a related aspect, it is also an object of the present invention, in view of the discovery of cellular kinases 40 specifically involved in CMV growth in a cell, to provide an assay component specially useful for detecting CMV in an individual (or a cell). Preferably the assay component comprises oligonucleotides capable of detecting activity of one or more of the cellular kinases RICK, RIP, NIK, MKK3, and SRPK-2 in a sample (e.g., by hybridization to mRNA from the sample), immobilized on a solid support. Most preferably the solid support would contain oligonucleotides of sufficient quality and quantity to detect all of the above-mentioned cellular kinases (e.g., a nucleic acid microarray).

[0064] Similarly, it is part of the object of the invention to provide an assay component specially useful for screening 45 compounds useful for treating CMV. One preferred assay component comprises oligonucleotides that encode one or more of the cellular kinases RICK, RIP, NIK, MKK3, and SRPK-2, immobilized on a solid support. In another embodiment, the assay component comprises peptide fragments of one or more of the above-identified cellular kinases immobilized on a solid support. Once again the most preferred solid support embodiment would contain polymers of sufficient quality and quantity to detect all of the above-mentioned cellular kinases (e.g., a nucleic acid or a peptide microarray). A variety of assay supports and construction of the same are well known in the art and easily adapted for 50 this purpose by a skilled practitioner (see, for example: Marshall, 1999. "Do-it-yourself gene watching" *Science* 286: 444-447 (including insets); and Service, 2000. "Protein arrays step out of DNA's shadow" *Science* 289:1673).

[0065] It is preferred that mRNA is assayed as an indication of expression. Methods for assaying for mRNA include, 55 but are not limited to, Northern blots, slot blots, dot blots, and hybridization to an ordered array of oligonucleotides. Nucleic acid probes useful for assay of a sample are preferably of sufficient length to specifically hybridize only to appropriate, complementary transcripts. Typically the oligonucleotide probes will be at least 10, 12, 14, 16, 18, 20 or 25 nucleotides in length. In some cases longer probes of at least 30, 40, or 50 nucleotides will be desirable.

[0066] The cDNA oligonucleotides immobilized on said membrane filter which are used for detecting the up- or down-regulation of the above-mentioned human cellular protein kinases by hybridization to the radioactively labeled cDNA probes have the nucleotide sequences listed in table 3.

Table 3:

| Nucleotide sequences of cDNA-arrays | |
|-------------------------------------|--|
| Human cellular kinase | Sequence of immobilized DNA on arrays (in relation to the respective Acc No) |
| RICK | 914 bp - 2501 bp (AF027706) |
| RIP | 1421 bp - 2617 bp (U50062) |
| NIK | 231 bp - 3077 bp (Y10256) |
| MKK3 | 341 bp - 2030 bp (NM_002756) |
| SRPK-2 | 1238 bp - 2790 bp (U88666) |

[0067] The nucleoside sequences of the genes coding for the human cellular protein kinases RICK, RIP, NIK, MKK3, and SRPK-2 listed in Table 3 together with the amino acid sequences of said enzymes can be obtained from NCBI (National Library of Medicine: PubMed; Web address: www.ncbi.nlm.nih.gov/entrez). Sequence protocols of the five cellular protein kinases are attached to this application as a part of the description.

[0068] The polypeptide product of gene expression may be assayed to determine the amount of expression as well. Methods for assaying for a protein include, but are not limited to, Western blot, immunoprecipitation, radioimmunoassay and peptide immobilization in an ordered array. It is understood, however, that any method for specifically and quantitatively measuring a specific protein or mRNA product can be used.

[0069] A variety of supports upon which nucleic acids or peptides can be immobilized are known in the art, for example filters, or polyvinyl chloride dishes. Any solid surface to which oligonucleotides or peptides can be bound, either directly or indirectly, either covalently or non-covalently, can be used. A preferred solid support is a microarray membrane filter or a "biochip". These contain particular polymer probes in predetermined locations on the array. Each predetermined location may contain more than one molecule of the probe, but each molecule within the predetermined location has an identical sequence.

[0070] The present invention incorporates by reference in their entirety techniques well known in the field of molecular biology. These techniques include, but are not limited to, techniques described in the following publications:

Ausubel, F.M. et al. eds., Short Protocols In Molecular Biology (4th Ed. 1999) John Wiley & Sons, NY. (ISBN 0-471-32938-X).

Old, R.W. & S.B. Primrose, Principles of Gene Manipulation: An Introduction To Genetic Engineering (3d Ed. 1985) Blackwell Scientific Publications, Boston. Studies in Microbiology; V.2:409 pp. (ISBN 0-632-01318-4).

Miller, J.H. & M.P. Calos eds., Gene Transfer Vectors For Mammalian Cells (1987) Cold Spring Harbor Laboratory Press, NY. 169 pp. (ISBN 0-87969-198-0).

Mayer, R.J. & J.H. Walker eds., Immunochemical Methods In Cell and Molecular Biology (1987) Academic Press, London. 325 pp. (ISBN 0-12480-855-7).

Sambrook, J. et al. eds., Molecular Cloning: A Laboratory Manual (2d Ed. 1989) Cold Spring Harbor Laboratory Press, NY. Vols. 1-3. (ISBN 0-87969-309-6).

Winnacker, E.L. From Genes To Clones: Introduction To Gene Technology (1987) VCH Publishers, NY (translated by Horst Ibelgauf). 634 pp. (ISBN 0-89573-614-4).

[0071] The present invention further incorporates by reference in their entirety techniques well known in the field of microarray construction and analysis. These techniques include, but are not limited to, techniques described in the following patents and patent applications describing arrays of biopolymeric compounds and methods for their fabrication: U.S. Pat. Nos. 5,242,974; 5,384,261; 5,405,783; 5,412,087; 5,424,186; 5,429,807; 5,436,327; 5,445,934; 5,472,672; 5,527,681; 5,529,756; 5,545,531; 5,554,501; 5,556,752; 5,561,071; 5,599,895; 5,624,711; 5,639,603; 5,658,734; 5,807,522; 6,087,102; WO 93/17126; WO 95/11995; WO 95/35505; EP 742 287; and EP 799 897. Techniques also include, but are not limited to, techniques described in the following patents and patent application describing methods of using arrays in various applications: U.S. Pat. Nos. 5,143,854; 5,288,644; 5,324,633; 5,432,049; 5,470,710; 5,492,806; 5,503,980; 5,510,270; 5,525,464; 5,547,839; 5,580,732; 5,661,028; 5,994,076; 6,033,860; 6,040,138; 6,040,140; WO 95/21265; WO 96/31622; WO 97/10365; WO 97/27317; EP 373 203; and EP 785 280.

[0072] It is readily apparent to those skilled in the art that other suitable modifications and adaptations of the com-

positions and methods of the invention described herein are obvious and may be made without departing from the scope of the invention or the embodiments disclosed herein. Having now described the present invention in detail, the same will be more clearly understood by reference to the following examples, which are included for purposes of illustration only and are not intended to be limiting of the invention.

5

Examples

Materials and Methods

10 EXAMPLE 1:

Signal Transduction cDNA Microarray Construction

[0073] To study the cellular pathology associated HCMV, a unique microarray of more than 1100 signal transduction cDNAs was created.

[0074] In order to manufacture cDNA-arrays on membranes, the following strategy was employed: cDNAs encoding parts of or full length proteins of interest (referred to as "target cDNAs") were cloned into the plasmid BLUESCRIPT II KS⁺ (Stratagene, USA). Large scale purifications of these plasmids were performed according to standard techniques, and 200 μ l aliquots (1 μ g/ μ l plasmid concentration) were transferred into appropriate 96 well plates. The plates were then sealed with sealing tape, incubated for 10 minutes at 95°C, and chilled on ice for 5 minutes. 10 μ l of 0.6N NaOH were added, and the mix was then stored for 20 minutes at room temperature. Following the incubation at room temperature, 10 μ l 2.5M Tris-HCl (Tris-(hydroxymethyl)-aminomethane-hydrochloride) pH7.1 and 20 μ l 40x SSC (6M Sodium chloride - 0.6M tri-Sodium citrate buffer) was added.

[0075] Target cDNAs were spotted onto Nylon or Nitrocellulose membranes using a BIOGRID (BioRobotics, UK) equipped with a 0.7mm pintool. 200-350ng of plasmid-encoding target cDNAs were transferred onto the membranes and crosslinked to the membranes using ultraviolet light ($1.2 \times 10^5 \mu\text{J}/\text{cm}^2$) treatment. The arrays were stored for use in subsequent experiments (described below) at room temperature.

EXAMPLE 2:

HCMV Infection

[0076] To examine the effects of HCMV infection on cellular signal transduction activity, HCMV-infected cells were generated for comparison to control (i.e., uninfected) cells.

[0077] Primary human foreskin fibroblasts (HFF) were grown close to confluence in MEM medium (Minimum Essential Medium, Life Technologies) supplemented with 20% fetal calf serum at 37°C and 5% CO₂ to obtain $\sim 6 \times 10^6$ cells per tissue culture flask. Virus adsorption to the cells was performed with the HCMV strain AD169 at different (0.2, 1, and 3) multiplicities of infection (MOI) for 90 minutes in a volume of 5ml at 37°C. The viral inoculum was removed, and cells were cultured in 50ml of MEM medium supplemented with 20% fetal calf serum and 150 μ g/ml cycloheximide at 37°C and 5%CO₂ for 7, 24, 48, or 72 hours, respectively.

EXAMPLE 3:

Isolation and Purification of Poly A⁺ RNA

[0078] In order to perform differential expression analysis using the cDNA microarray described in Example 1, RNA extraction and purification on the HCMV-infected and uninfected cells was performed using techniques known in the art.

[0079] Briefly, after incubation (for the respective time-intervals) of infected and control cells, cells were washed twice with phosphate buffered saline (PBS) and then trypsinized. Cells were removed from the culture dish by resuspension with PBS. Cells were then sedimented, and directly lysed by repetitive pipetting in 1ml of Tri reagent (Molecular Research Centre, Inc., USA) per 1×10^6 cells.

[0080] Cell lysates were stored at room temperature for 5 minutes, and then centrifuged (12,000xg) for 15 minutes at 4°C. The supernatant was mixed with 0.1ml of 1-bromo-3-chloropropane per 1ml of Tri reagent and shaken vigorously. The resultant suspension was stored for 5 minutes at room temperature, and then centrifuged (12,000xg) for 15 minutes at 4°C.

[0081] Following centrifugation, the colorless upper phase was transferred into new tubes, mixed with 5 μ l of polyacryl-carrier (Molecular Research Centre, Inc., USA), and vigorously shaken with 0.5ml of isopropanol per 1ml of Tri reagent. The samples were stored at room temperature for 5 minutes and then centrifuged (12,000xg) for 8 minutes

at 4°C. The supernatant was removed and the RNA pellet washed twice with 1ml of 75% ethanol. The pellet was dried and resuspended in RNase-free buffer at a concentration of 1µg RNA per 1µl buffer.

[0082] Purification of poly A⁺ RNA from total RNA was performed using the OLIGOTEX system (Qiagen, Germany) following manufacturer's instructions. In brief, 100-200µg of total RNA was brought up to 250µl with RNase-free water, and 250µl of buffer OBB (20mM Tris/HCl pH7.5, 1M NaCl, 2mM EDTA, 0.2% SDS) and 15µl of OLIGOTEX suspension was added. The samples were incubated for 3 minutes at 70°C, and placed at room temperature for 10 minutes. The samples were centrifuged for 2 minutes (12,000xg), and the supernatant removed. The remaining pellet was resuspended in 400µl buffer OW2 (10mM Tris/HCl pH7.5, 150mM NaCl, 1mM EDTA). The suspension was transferred to a spin column (supplied with the system) and centrifuged at 12000xg for 1 minute at room temperature. The spin column was transferred to a new tube and 400 µl of buffer OW2 was applied on the column. The spin column was centrifuged (12,000xg) for 1 minute at room temperature. The spin column was transferred to a new tube and the RNA eluted from the column by the addition of 50µl buffer OEB (5mM Tris/HCl pH7.5) (at 70°C) to the column, resuspension of the Oligotex-resin, and centrifugation (12,000xg) for 1 minute at room temperature.

[0083] Any genomic DNA contamination of the RNA preparations was eliminated by enzymatic digestion using DNase I. 6µl of 10x DNase buffer (Promega, USA) and 4µl of RQ-DNase (Promega, USA) were added to 50µl of the RNA-buffer solution, and the reaction mixture was incubated for 15 minutes at 37°C. Stop-buffer (6µl; Promega, USA) was then added, the mixture brought to 200 µl final volume with TE buffer (10mM Tris/HCl, 1mM EDTA), and Phenol/Chloroform extractions were performed twice. The RNA-containing phase was transferred to new reaction tubes and RNA was precipitated using 5M NaCl (final concentration of 0.2M), 1µl poly-acryl-carrier (Molecular Research Centre, Inc., USA) and 500 µl of 100% ethanol. The solution was centrifuged for 10 minutes at 4°C, the RNA pellet washed with 1ml of 80% ethanol, dried, and resuspended in 30µl TE buffer. Poly A⁺ RNA suspension samples were stored at -70°C for use in subsequent experiments.

EXAMPLE 4:

Preparation of Radioactively Labeled cDNA Probes from RNA

[0084] To prepare test and control samples for microarray analysis, RNA samples isolated and purified from HCMV-infected and control cells (prepared as described in Example 3) were used to generate radioactively labeled cDNA probe. Many techniques to generate labeled cDNA constructs from cellular RNA extracts are known in the art and applicable to the present invention. Two of those protocols were used in this example to generate radiolabeled cDNA from RNA samples: the first technique involved reverse transcribing cDNA from the RNA sample in the presence of radioactively labelled dATP; the second technique involved first strand cDNA synthesis from the RNA sample, followed by random priming with radioactively labelled dATP.

[0085] For reverse transcription of cDNA from the RNA sample in the presence of radioactively labelled dATP, 1µg of primer TXN (5'-TTT TTT TTT TTT TXN-3'; SEQ ID NO:1; with T = dTTP; N = dATP, dCTP, dGTP or dTTP; X = dATP, dCTP or dGTP) and total RNA (1 to 15 µg) or poly A⁺ RNA (20 to 500 ng) were combined in 12 µl bidistilled DEPC-treated H₂O (DEPC: diethylpyrocarbonate) and shaken for 5-15 minutes at 60°C. The mixture was then incubated at 4°C for 2-10 minutes, and centrifuged (10,000xg) for 30 seconds.

[0086] After centrifugation, 7µl of a labelling mix (100µCi γ [³²P]-ATP (Amersham, UK); vacuum dried and resuspended in 4µl first strand buffer (Life Technologies, USA); 2µl 0.1M DTT (dithiothreitol); and 1µl labelling solution -- 4mM dCTP, dGTP, dTTP each and 80 µM dATP final concentration) was added to the RNA solution. 1µl SUPERSCRIPT II reverse transcriptase (Life Technologies, USA) was added and the reaction incubated for 10 minutes at room temperature and then for 60 minutes at 38°C. Following the reaction incubation, 5µl 0.5M EDTA (ethylene diamine tetraacetate) and 25 µl 0.6M NaOH was added to the reaction mixture and shaken vigorously for 30 minutes at 68°C.

[0087] Unincorporated nucleotides were removed from the labelling reaction using PROBEQUANT G-50 columns (Amersham, UK). The column (with bottom closure and lid removed) was shaken vigorously and centrifuged (735xg) for 1 minute in an appropriate reaction tube. The column was placed into a new reaction tube, the probe was applied onto the center of the column material and the column was centrifuged (735xg) for 2 minutes. The flow-through was transferred into new reaction tubes and bidistilled H₂O added to 100 µl final volume. 5M NaCl, 1µl poly-acryl-carrier (Molecular Research Centre, Inc., USA) and 250 µl ethanol was added, and the probe precipitated by centrifugation (12,000xg) for 15 minutes. The supernatant was discarded and the pellet dried for subsequent use.

[0088] For the alternate labelling technique (random priming with radioactively labelled dATP after first strand cDNA synthesis), the following procedure was followed: 1µg primer TXN (see above) was added to 20-500ng of poly A⁺ RNA in 12 µl final volume, incubated for 5 minutes at 60°C, followed by an addition incubation for 2-10 minutes on ice. The mix was centrifuged (12,000xg) for 30 seconds, and 4µl of first strand buffer (Life Technologies, USA), 2µl 0.1M DTT, 1µl 10mM dNTP and 1µl SUPERSCRIPT II reverse transcriptase (Life Technologies, USA) was added. The reaction was incubated for 10 minutes at room temperature, followed by an additional incubation for 60 minutes at 38°C. Fol-

lowing the reaction incubation, 5 μ l 0.5M EDTA and 25 μ l 0.6M NaOH was added to the reaction mixture and shaken vigorously for 30 minutes at 68°C.

[0089] Unincorporated nucleotides were removed as described above; however, the final pellet was resuspended in 30 μ l bidistilled H₂O.

5 [0090] 15 μ l of the resuspended cDNA solution was transferred to new reaction tubes, incubated for 5 minutes at 95°C, chilled on ice for 5 minutes, and centrifuged for 30 seconds. Following manufacturer's instructions accompanying the Random Primers DNA Labelling system (Life technologies, USA), 15 μ l buffers mixture, 2 μ l of each dCTP, dGTP and dTTP (provided with the system) were added to the cDNA. 5 μ l γ [³³P]-ATP (Amersham, UK) was added and the mixture adjusted to 49 μ l final volume with bidistilled H₂O. The reaction was started by addition of 1 μ l Klenow enzyme (supplied with the system), and incubated for 60 minutes at 25°C 5 μ l. Stop solution (provided with the system) was added and unincorporated nucleotides were removed by column purification as described above.

10

EXAMPLE 5:

15 Hybridization of Labeled cDNA Probe to cDNA Array

[0091] To screen HCMV-infected cells compared to uninfected cells for differential activation of cellular signal transduction, labeled cDNA probes (generated according to Example 4) were exposed to a signal transduction cDNA microarray (generated as described in Example 1) following hybridization techniques known in the art.

20 [0092] Sample pellets from Example 4 were resuspended in 10 μ l C₀T DNA (1 μ g/ μ l, Roche Diagnostics, Germany), 10 μ l yeast tRNA (1 μ g/ μ l Sigma, USA) and 10 μ l poly A (1 μ g/ μ l, Roche Diagnostics, Germany). Herring sperm DNA (to a final concentration of 100 μ g/ml), 5 μ l 10% SDS (Sodiumdodecylsulfate), and 25 μ l 20x SSPE was added, and adjusted 100 μ l final volume with bidistilled H₂O. The mix was incubated for 5 minutes at 95°C, centrifuged (10,000xg) for 30 seconds, and vigorously shaken for 60 minutes at 68°C. A 1 μ l aliquot of the probe was used to measure the incorporation of radioactive dATP with a scintillation counter. Probes with at least a total of 20x10⁶ cpm were used for the screen assay.

25

[0093] Arrays were prehybridized in hybridization solution for at least 30 minutes in a roller bottle oven at 42°C. Following prehybridization, radiolabelled probe was added to the hybridization solution and hybridization was continued for 20-40 hours.

30 [0094] Following hybridization, the probe was discarded and the array subjected to a series of washes. Initially the arrays were washed twice in wash solution A (2xSSC) in the roller oven at room temperature. Wash solution A was then replaced with wash solution B (2x SSC, 0.5% SDS), preheated to 60°C, and arrays were washed twice for 30 minutes at 60°C. Wash solution B was then replaced with wash solution C (0.5x SSC, 0.5% SDS), preheated to 60°C, and arrays were washed twice for 30 minutes at 60°C.

35 [0095] The moist arrays were wrapped in airtight bags and exposed for 8-72 hours on erased phosphoimager screens (Fujifilm, Japan).

EXAMPLE 6:

40 Signal Transduction cDNA Array Analysis

[0096] To demonstrate differential activation of cellular signal transduction in HCMV-infected cells compared to uninfected cells, hybridized cDNA arrays from infected and uninfected samples were analyzed.

45 [0097] Exposed phosphoimager screens (from Example 5) were scanned with a resolution of 100 μ and 16bits per pixel using a BAS-1800 (Fujifilm, Japan). The data were imported into the computer program, ARRAYVISION (Imaging Research, Canada), and analyzed according the computer program's specification. Hybridization signal strength is indicative of the quantity of RNA molecules present in the probe. Differentially expressed genes were identified according to the ratio of signal strength after normalization to the overall intensity of the arrays.

50 [0098] Signal transduction cDNA microarray analysis of radiolabelled cDNA-probes from HCMV-infected (strain AD169) versus non-infected primary human foreskin fibroblasts to cDNA-arrays revealed significant upregulation of the cellular kinase cDNAs:

RICK (2-fold at 3 hours post infection; 3.6-fold at 7 hours post infection);
 RIP (2.6-fold at 3 hour post infection; 2.2-fold at 24 hour post infection);
 55 NIK (4-fold at 7 hour post infection);
 MKK3 (2-fold at 3 hour post infection; 2.5-fold at 7 hour post infection); and
 SRPK-2 (2.2-fold at 7 hour post infection)

compared to uninfected human foreskin fibroblasts cells.

EXAMPLE 7:

5 Northern Blot Analysis

[0099] To confirm the results of the microarray analysis of Example 6, northern blot analysis was performed according to techniques well known in the art.

10 [0100] HCMV-infected and uninfected cells (from Example 2) cells were pelleted and the total RNA was prepared as follows: Following centrifugation and removal of the supernatant, cells were lysed in 1ml of Trizol reagent (ready-to-use-reagent from Gibco-BRL) per 1.5×10^6 cells. The Tri reagent/cell lysate was transferred to an eppendorff tube and centrifuged (13,000rpm) for 15 minutes at 4°C. The supernatant was transferred to a new eppendorff tube and 0.1ml of BCP (1-bromo-3-chloropropane) for each ml of Tri reagent was added. Samples were vortexed for 15 seconds, incubated for 5 min at room temperature, and then centrifuged (13,000rpm) for 15 minutes at 4°C. The upper aqueous phase was transferred to a new eppendorff tube, 0.5 ml isopropanol was added for each ml of Tri reagent (Molecular Research Center, Inc., USA), vortexed, and incubated for additional 8 min at room temperature, and centrifuged (13,000rpm) for 10 min at 4°C. The supernatant was aspirated, and the precipitated RNA was washed twice with ice-cold 75% ethanol and air-dried. The RNA pellet was resuspended in 50 μ l Tris-HCl pH 7.5.

15 [0101] The quantity of the RNA for each sample was determined by UV-spectroscopy, and the quality was determined via gel electrophoresis on a formaldehyde-containing 1.2% agarose gel.

20 [0102] RNA samples of 10 μ g each were size-fractionated by 1.2% formaldehyde agarose gel electrophoresis and transferred to synthetic membrane filters (Hybond N, Amersham) with 20XSSC (1 X SSC is 150 mM NaCl, 15 mM $C_6H_5Na_3O_7 \times 2H_2O$, pH 7.0) overnight. RNA was immobilized to the filter using UV-light for crosslinking (120 mJ/cm² for 25 seconds).

25 [0103] Membrane filters were firstly prehybridized for 4 hours at 65°C in a prehybridization solution containing 5 X SSC, 10 X Denhardt's solution (1 X Denhardt's solution is 0.02% bovine serum albumine, 0.02% polyvinyl pyrrolidone, 0.02% ficoll), 20mM sodium phosphate, pH 7.0, 7% SDS, 100 μ g/ml sonicated salmon sperm DNA, and 100 μ g/ml. Hybridization was performed at 65°C in the prehybridization buffer containing 10% dextran sulphate, plus added radiolabelled probe for 16 hours.

30 [0104] Membrane filters were hybridized to oligonucleotide probes specific for a particular cellular kinase identified in Example 6. Probes sequences included the following:

35 **Table 4:**

| Cellular Kinase | cDNA Probe Sequence | SEQ ID NO: |
|-----------------|--|------------|
| NIK | 5'- GTC CTG GAG GGC TCT TTT TGA TGA AAC C - 3' | 2 |
| RIP | 5'- GTG CTC AAT GCA GTT GGG CCC CTT GTA CAC-3' | 3 |
| RICK | 5'- GTC GAG CAG CGG AGT GTG GAT GTG CAG - 3' | 4 |

45

[0105] The oligonucleotides were radiolabelled at their 3' ends with (alpha-32P) deoxyadenosine 5'- triphosphate (^{32}P - α -dATP) (Amersham) employing the Terminal Transferase kit (Roche) following manufacturer's instructions.

50 [0106] Unincorporated ^{32}P - α -dATP nucleotides were removed similar to the protocol described in Example 4: After vortexing the PROBEQUANT Sephadex G-50 (Amersham, UK) column (with bottom closure and lid removed), the column was placed in a 2 ml tube and centrifuged for 1 minute at 735xg. The column was placed in a new 1.5ml eppendorff tube (without a cap), and the radioactive probe was pipetted carefully on the center of the preformed resin. Centrifugation (735xg) for 2 minutes effectively removed the unincorporated ^{32}P - α -dATP nucleotides.

55 [0107] Hybridized filters were washed once in 5% SDS, 3 X SSC, 10 X Denhardt's solution, 20mM sodium phosphate, pH 7.0 for 30 min at 65°C. A second wash step followed in 1 X SSC, 1% SDS at 65°C for 30 min.

[0108] Filters were exposed at -80°C to Kodak XAR-5 films using intensifying screens.

[0109] Northern blot analysis confirmed upregulation of cellular kinase mRNA: RICK, RIP, and NIK in HCMV-infected cells compared to uninfected cells, consistent with results obtained from microarray analysis.

EXAMPLE 8:

Western Blot Analysis

5 [0110] To further confirm the results of the microarray analysis of Example 6 and northern blot analysis of Example 7, western blot analysis was performed according to techniques well known in the art.

10 [0111] HCMV-infected and uninfected cells (from Example 2) were pelleted and polypeptide extracts prepared as follows: Infected and uninfected cell samples (from various time intervals) were lysed with 420 μ l of lysis buffer (20mM Hepes (N-[2-hydroxyethyl]piperazine-N'-[2-ethansulfonic acid]) pH7.5, 150 mM NaCl, 1% TRITON X-100 (t-octylphenoxypolyethoxyethanol), 10% glycerol, 1mM PMSF (phenylmethylsulfonyl fluoride), 10 μ g/ml Aprotinin, 1mM orthovanadat) on ice. Lysed cells were cleared from debris by centrifugation (15 minutes, 13000 rpm, 4°C), dissolved in 1x Laemmli buffer, denatured for 5 minutes at 100°C and submitted to SDS-PAGE (gradient gel 7% - 12%).

15 [0112] Gels were blotted onto nitrocellulose filters (Amersham, UK) for 3 hours (0.8mA/cm2). Detection of expression of the identified host cell kinases was performed using the following target specific antibodies: OPA1-01023 polyclonal rabbit anti-RICK antibody (Dianova); H-207 polyclonal rabbit anti-RIP antibody (Santa Cruz Biotechnology); I-20 polyclonal rabbit anti-MKK3 antibody (Santa Cruz Biotechnology); S80620 murine anti-SRK2 antibody (Transduction Laboratories); anti-NIK rabbit serum (generated by SIGMA Genosys Biotechnologies using the NIK-peptide 5'-CNPT-NTRPQSDTPEIRKYKKRFN-3', SEQ ID NO:5, for immunization). All antibodies were used according to the manufacturer's instructions. Detections were performed with the ECL Kit (Amersham, UK).

20 [0113] Western blot analysis confirmed the transcriptional upregulation of infected host cell kinase mRNAs resulted in increased expression of the respective proteins:

A single ~60kDa band representing RICK was upregulated between 7-24 hours post HCMV infection;
 A single ~74kDa band representing RIP was upregulated between 7-72 hours post HCMV infection;
 A single ~135kDa band representing NIK was upregulated between 24-72 hours post HCMV infection;
 A single ~35kDa band representing MKK3 was upregulated between 7-72 hours post HCMV infection; and
 A single ~115kDa band representing SRK2 was upregulated between 24-72 hours post HCMV infection.

EXAMPLE 9:

30 [0114] HFF cells were infected with Adenovirus expressing various kinase constructs at different particles per cell ratios (p/c). The adenovirus used here were all E1, E3 defective derivatives of adenovirus type 5 (reviewed in Russell 35 WC (2000) Update on adenovirus and its vectors. *J Gen Virol.* 81:2573-604). Briefly, the cDNA of interest was cloned into a transfer plasmid bearing the CMV IE promoter enhancer (IE: immediate early) and the rabbit beta-globin intron/polyadenylation signal. This expression cassette was inserted into a bacterial plasmid borne-adenovirus genome using recombination in bacteria (Chartier C., E. Degryse, M. Gantzer, A. Dieterle, A. Pavirani, and M. Mehtali. 1996. Efficient generation of recombinant adenovirus vectors by homologous recombination in *Escherichia coli*. *J. Virol.* 70: 4805-4810.). Virus was amplified in HEK 293 cells and purified from cell lysates using CsCl density gradient centrifugation as described (Cotten, M., Baker A., Birnstiel M.L., Zatloukal, K., Wagner, E. (1996) Adenovirus polylysine DNA conjugates. in Current Protocols in Human Genetics, Eds. N. C. Dracopoli, J. L. Haines, B.R. Korf, D.T. Moir, C.C. Morton, C.E. Seidman, J.G. Seidman, D.R. Smith; John Wiley and Sons, Inc. New York, pp. 12.3.1-12.3.33.). The control viruses AdJ5 was previously described (Glotzer J.B., Saltik M., Chiocca S., Michou A.I., Moseley P. and Cotten 40 M. (2000) Activation of heat-shock response by an adenovirus is essential for virus replication. *Nature* 407:207-11).

45 [0115] Two days after plating HFF cells, cultures were infected with CMV strain Ad169-GFP. Replication of CMV was estimated after one week (7 dpi) utilizing the GFP-signal expressed as GFP counts.

50 [0116] Fig. 1 shows the reduction rates in HCMV replication of HFF cells pre-infected with Adeno virus containing the RIP wildtype sequence (AdRIPwt; 1 - 4) and a RIP inactive mutant (AdRIPkr; 5 - 8).

55 [0117] No HCMV-infection resulted in hardly any signal (mock, 13), while infection with HCMV yielded in about 13.000 GFP counts (AD169-GFP; 14). Pre-infection with increasing amounts of control Adeno virus (AdliteJ5) caused a slight reduction in HCMV replication (9 - 12). There was a clear difference, when HFF cells were pre-infected with Adeno virus containing the RIP wildtype sequence (AdRIPwt; 1 - 4) and a RIP inactive mutant (AdRIPkr; 5 - 8). The lysine (K) at amino acid position 45 is mutated to an arginine (R), which renders the kinase inactive. This mutation was introduced into the human RIP cDNA utilizing the QuikChangeTM Site-directed Mutagenesis Kit (Stratagene, CA, USA) according to the instructions of the manufacturer. Expression of the mutated RIP kinase efficiently blocked HCMV replication (5 - 8), while the wildtype sequence was less potent in doing so (1 - 4).

[0118] Fig. 2 shows the reduction rates in HCMV replication of HFF cells pre-infected with Adeno virus containing

the RICK wildtype sequence (AdRICKwt) and two RICK inactive mutants (AdRICKkr and AdRICKdn). In one construct (AdRICKkr), the lysine (K) at position 47 is mutated to an arginine (R). In the other construct (AdRICKdn), the aspartate at position 146 is mutated to an asparagine. Both changes in sequence render the kinase inactive. The mutations were introduced into the human RICK cDNA utilizing the QuikChange™ Site-directed Mutagenesis Kit (Stratagene, CA, USA) according to the instructions of the manufacturer.

[0119] Similar experiments as described for RIP (Example 9, Fig. 1) were also performed with RICK. No HCMV-infection resulted in hardly any signal (Mock + Mock), while infection with HCMV yielded in about 7.000 GFP counts (Mock + AD169-GFP). Pre-infection with increasing amounts of control Adeno virus (AdliteJ5, from 111 to 3000 particles per cell) caused a slight reduction in HCMV replication. There was a clear difference, when HFF cells were pre-infected with Adeno virus containing the RICK wildtype sequence (AdRICKwt and two RICK inactive mutants (AdRICKkr and AdRICKdn). All three RICK constructs efficiently reduced HCMV-replication.

EXAMPLE 10:

15 RICK-Kinase Assay

[0120] To obtain active RICK kinase the human RICK-cDNA was fused with a DNA sequence coding for the HA-tag and cloned into the eucaryotic expression vector pcDNA3 (Invitrogen). This construct was transfected into human embryonic kidney cells (HEK 293) via the calcium-phosphate co-precipitation method. One day after transfection medium was replaced by fetal calf serum-free medium and two days after transfection cells were washed with PBS and harvested and lysed in RIPA-buffer (150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% Na-desoxycholate, 0.1 % SDS, 10 mM Tris-HCl pH 7.5). The RICK-HA fusion protein was immunoprecipitated from 250 µl cleared lysate (i.e. lysate of one well of a six-well plate) utilizing an anti-HA antibody from Roche Pharmaceuticals and Protein A sepharose. After addition of 500 µl of HNTG-buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 1 mM EDTA, 10% glycerine, 0.1% Triton X-100) the sample was rotated for 3 hrs at 4°C. After washing the immunoprecipitate twice with 0.5 ml HNTG-buffer and twice with 0.5 ml assay-buffer (25 mM Tris-HCl pH 7.5, 3 mM MgCl₂, 0.5 mM MnCl₂, 0.5 mM DTT and 50 mM NaCl), the kinase reaction was performed directly on the beads in 40 µl assay buffer containing 2.5 µCi $\gamma^{33}\text{P}$ -ATP and various concentrations (between 100 nM and 50 µM) of compounds of Table 1. After 30 min at 30°C, the reaction was stopped by addition of 40 µl 3X Laemmli-buffer (16% glycerol, 1.01M β -mercaptoethanol, 5% SDS, 200mM Tris/HCl pH 6.8, 8% bromphenolblue). Phosphorylation products were analyzed by SDS-PAGE and autoradiography (x-ray film and phosphor imager).

EXAMPLE 11:

35 RIP-Kinase Assay

[0121] To obtain active RIP kinase the human RIP-cDNA was fused with a DNA sequence coding for the HA-tag and cloned into the eucaryotic expression vector pcDNA3 (Invitrogen). This construct was transfected into human embryonic kidney cells (HEK 293) via the calcium-phosphate DNA co-precipitation method. Two days after transfection cells were washed with PBS and harvested and lysed in lysis-buffer (150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 20 mM Tris-HCl pH 7.5 and freshly added: 30 mM NaF, 10 µg/ml Aprotinine, 10 µg/ml Leupeptine, 2 mM Na-pyrophosphate). The RIP-HA fusion protein was immunoprecipitated from 250 µl cleared lysate (i.e. lysate of one well of a six-well plate) utilizing an anti-HA antibody from Roche Pharmaceuticals and Protein A sepharose. The sample was rotated for 3 hrs at 4°C. The immunoprecipitates were washed twice with 0.75 ml lysis-buffer, twice with 0.75 ml high salt-buffer (1 M NaCl, 1 mM EDTA, 1% Triton X-100, 20 mM Tris-HCl pH 7.5 and freshly added: 30 mM NaF, 10 µg/ml Aprotinine, 10 µg/ml Leupeptine, 2 mM Na-pyrophosphate), twice with 0.75 ml lysis-buffer and twice 0.75 ml with kinase assay buffer (10 mM MgCl₂, 10 mM MnCl₂, 10 mM benzamidine, 0.5 mM EDTA). The kinase reaction was performed directly on the beads in 40 µl kinase assay buffer containing 2.5 µCi $\gamma^{32}\text{P}$ -ATP and various concentrations (between 100 nM and 50 µM) of compounds of Table 2. After 30 min at 30°C, the reaction was stopped by addition of 40 µl 2X Laemmli-buffer. Phosphorylation products were analyzed by SDS-PAGE and autoradiography (x-ray film and phosphor imager).

EXAMPLE 12:

55 Virus Replication Assay

Cell culture and virus

[0122] Primary human foreskin fibroblasts (HFF) were cultivated in MEM containing 5% (v/v) fetal calf serum. Infec-

tion analysis was restricted to cell passage numbers below twenty. Human cytomegalovirus strain AD169 (ATCC) was grown in HFF cells and quantitated for infectivity by the plaque reduction assay. Aliquots were stored at -80°C.

Construction of recombinant cytomegalovirus

[0123] For construction of a recombination vector, two linker sequences were inserted into the pBlueScribe vector pBS+ (Stratagene): the first contained restriction sites for NheI, SphI, PstI and BglII followed by a loxP sequence (ATAACTTCGTATAGCATACATTACGAAGTTAT) and was introduced into PstI/XbaI sites of the vector; the second contained another loxP sequence followed by restriction sites HpaI, ClaI and PmeI and was introduced into BamHI/Asp718 sites. A gene cassette comprising of a "humanized" version of the ORF coding for GFP (gfp-h) under the control of the HCMV enhancer/promoter and the Ptk/PY441 enhancer-driven neoR selection marker was excised from plasmid pUF5 (Zolotukhin et al., 1996, J. Virol. 70, 4646-4654) and inserted into the recombination vector via BglII sites. [0124] At the 5' and 3'-positions of this loxP-flanked gene cassette, two HCMV sequences with homology to the gene region containing the open reading frames US9 and US10 were inserted. For this, viral sequences were amplified from template pCM49 (Fleckenstein et al., 1982, Gene 18, 39-46) via PCR in a 35-cycle program (denaturation 45 sec at 95°C, annealing 45 sec at 55°C and elongation 2 min at 72°C) by the use of Vent DNA polymerase (New England Biolabs). A US10-specific sequence of 1983 bp in length was generated using primers US10[200900]SphI (GCT-CACTAGTGGCCTAGCCTGGCTATGGCC) and US10[198918]PacI (GTCCTTAATTAAGACGTGGTTGGTCAC-CGAA) and inserted at the vector 5' cloning position via SphI/PacI restriction sites (see bold-print). A US9-specific sequence of 2010 bp was generated using primers US9-3'PmeI (CTCGGTTAACGACGTGAGGCGCTCCGTCACC) and US-5' ClaI (TTGCATCGATACGGTGTGAGATACCACGATG) inserted at the vector 3' cloning position via PmeI/ClaI restriction sites. [0125] The resulting construct pHM673 was linearized by the use of restriction enzyme NheI and transfected into HEF cells via the electroporation method using a Gene Pulser (Bio-rad; 280 V, 960 µF, 400 Ω). After 24 h of cultivation, cells were used for infection with 1 PFU/ml of HCMV strain AD169. Selection with 200 µg/ml G418 was started 24 h post infection. Following 3 weeks of passage in the presence of G418, GFP fluorescence could be detected in most of the infected cells. Plaque assays were performed with infectious culture supernatant on HFF cells and single virus plaques were grown by transfer to fresh HFF cells cultured in 48-well plates. DNA was isolated from cells of 32 fluorescence-positive wells and confirmed for the presence of recombinant virus by PCR. For this, primers US9[198789] (TGACGCGAGTATTACGTGTC) and US10[199100] (CTCCTCCTGATATGCGGTT) were used resulting in an amplification product of 312 bp for wild-type AD169 virus and approximately 3.5 kb for recombinant virus.

Plaque assay

[0126] HFF cells were cultivated in 12-well plates to 90-100% confluence and used for infection with dilutions of virus-positive cell culture supernatants. Virus inoculation was performed for 90 min at 37°C under occasional shaking before virus was removed and the cell layers were rinsed with PBS. Overlays of MEM 5% (v/v) fetal calf serum and 0.3% (w/v) agarose were added to each well and all samples were incubated at 37°C in a 5% CO₂ atmosphere for approximately 12 days. Finally, overlays were removed and the formation of foci was visualized by staining with 1% crystal violet in 20% ethanol for 1 min. After repeated rinsing with PBS, plates were air-dried at room temperature and plaque numbers were counted with a light microscope. For the recombinant AD169-GFP virus, quantification of plaque assays could also be performed without crystal violet staining by a direct counting of the amount of green fluorescent plaques using fluorescence microscopy.

Antiviral compounds

[0127] The reference compounds used for antiviral studies, ganciclovir (GCV, Cymeven), foscarnet sodium (FOS, Foscavir) and cidofovir (CDV, Vistide) were purchased from Syntex Arzneimittel (Aachen, Germany), Sigma-Aldrich (Germany) and Pharmacia & Upjohn S.A. (Luxembourg), respectively. Stocks were prepared in aqueous solution and stored at -20°C. The test compounds were dissolved in DMSO and aliquots were stored at -20°C.

GFP infection assay

[0128] HFF cells were cultivated in 12-well plates to 90-100% confluence and used for infection with 0,5xTCID₅₀ of AD169-GFP virus. Virus inoculation was performed for 90 min at 37°C with occasional shaking before virus was removed and the cell layers were rinsed with PBS. Infected cell layers were incubated with 2 ml of MEM containing 5% (v/v) fetal calf serum and optionally of the respective test substances or DMSO as control. Infected cells were incubated at 37°C in a 5% CO₂ atmosphere for 7 days and harvested by trypsinization and centrifugation. 200 µl of lysis buffer (25

5 mM Tris pH 7.8, 2 mM DTT, 2 mM trans-1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid, 1% Triton X-100, 10% glycerol) was added to each cell pellet and lysis was achieved by incubation for 10 min at 37°C followed by a 30-min incubation at room temperature on a shaker. Lysates were centrifuged for 5 min at 15.000 rpm in an Eppendorf centrifuge to remove cell debris. Supernatants were transferred to an opaque 96-well plate for automated measuring of GFP signals in a Victor 1420 Multilabel Counter (Wallac). GFP units were converted to percent inhibition values relative to DMSO controls (set at 100% GFP expression).

Indirect immunofluorescence analysis

10 [0129] Cells were either grown on Lab-Tek Permanox slides (Nunc) or harvested from 6-well plates, spotted onto glass slides with marked rings (Medco) and fixed by a 15-min treatment with 3% formaldehyde in PBS followed by permeabilization for 15 min in 0.1% Triton X-100 in PBS at room temperature. Blocking was achieved by incubation with Cohn Fraction II/III of human gamma-globulin (Sigma; 2 mg/ml) for 30 min at 37°C. The IE1/IE2-specific primary antibody MAb810 (Chemicon International, Inc. CA, USA; dilution 1:10.000) was incubated for 90 min, the secondary antibody (tetramethyl rhodamine [TRITC]-coupled anti-mouse antibody, Dianova, dilution 1:100) for 45 min at 37°C before analysis by fluorescence microscopy. In addition to indirect TRITC staining of IE1/IE2 proteins, GFP signals could be detected directly via the fluorescence isothiocyanate (FITC) channel. Nuclear counterstaining was carried out using Vectashield mounting medium including DAPI (Vector Laboratories, Burlingame, CA).

20

25

30

35

40

45

50

55

SEQUENCE LISTING

5 <110> Axxima Pharmaceuticals AG
10 <120> CELLULAR KINASES INVOLVED IN CYTOMEGALOVIRUS INFECTION
15 <130> PA012EP
20 <140>
25 <141>
30 <160> 2
35 <170> PatentIn Ver. 2.1
40 <210> 1
45 <211> 2501
50 <212> DNA
55 <213> Homo sapiens
60 <220>
65 <221> CDS
70 <222> (225)..(1847)
75 <400> 1
80 ggcaccagtc tctagaaaaag aagtcaagtc tggttcggag aagcagcggc tggcgtggc 60
85 catccgggga atgggcgccc tcgtgaccta gtgttgcggg gcaaaaaggg tcttgccggc 120
90 ctcgctcgtg caggggcgtta tctggcgcc tgagcgcgca gtgggagcct tgggagccgc 180
95 cgcagcaggg ggcacaccccg gaaccggcct gagcgcggc gacc atg aac ggg gag 236
100 Met Asn Gly Glu
105 1
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500
505
510
515
520
525
530
535
540
545
550
555
560
565
570
575
580
585
590
595
600
605
610
615
620
625
630
635
640
645
650
655
660
665
670
675
680
685
690
695
700
705
710
715
720
725
730
735
740
745
750
755
760
765
770
775
780
785
790
795
800
805
810
815
820
825
830
835
840
845
850
855
860
865
870
875
880
885
890
895
900
905
910
915
920
925
930
935
940
945
950
955
960
965
970
975
980
985
990
995
1000
1005
1010
1015
1020
1025
1030
1035
1040
1045
1050
1055
1060
1065
1070
1075
1080
1085
1090
1095
1100
1105
1110
1115
1120
1125
1130
1135
1140
1145
1150
1155
1160
1165
1170
1175
1180
1185
1190
1195
1200
1205
1210
1215
1220
1225
1230
1235
1240
1245
1250
1255
1260
1265
1270
1275
1280
1285
1290
1295
1300
1305
1310
1315
1320
1325
1330
1335
1340
1345
1350
1355
1360
1365
1370
1375
1380
1385
1390
1395
1400
1405
1410
1415
1420
1425
1430
1435
1440
1445
1450
1455
1460
1465
1470
1475
1480
1485
1490
1495
1500
1505
1510
1515
1520
1525
1530
1535
1540
1545
1550
1555
1560
1565
1570
1575
1580
1585
1590
1595
1600
1605
1610
1615
1620
1625
1630
1635
1640
1645
1650
1655
1660
1665
1670
1675
1680
1685
1690
1695
1700
1705
1710
1715
1720
1725
1730
1735
1740
1745
1750
1755
1760
1765
1770
1775
1780
1785
1790
1795
1800
1805
1810
1815
1820
1825
1830
1835
1840
1845
1850
1855
1860
1865
1870
1875
1880
1885
1890
1895
1900
1905
1910
1915
1920
1925
1930
1935
1940
1945
1950
1955
1960
1965
1970
1975
1980
1985
1990
1995
2000
2005
2010
2015
2020
2025
2030
2035
2040
2045
2050
2055
2060
2065
2070
2075
2080
2085
2090
2095
2100
2105
2110
2115
2120
2125
2130
2135
2140
2145
2150
2155
2160
2165
2170
2175
2180
2185
2190
2195
2200
2205
2210
2215
2220
2225
2230
2235
2240
2245
2250
2255
2260
2265
2270
2275
2280
2285
2290
2295
2300
2305
2310
2315
2320
2325
2330
2335
2340
2345
2350
2355
2360
2365
2370
2375
2380
2385
2390
2395
2400
2405
2410
2415
2420
2425
2430
2435
2440
2445
2450
2455
2460
2465
2470
2475
2480
2485
2490
2495
2500
2505
2510
2515
2520
2525
2530
2535
2540
2545
2550
2555
2560
2565
2570
2575
2580
2585
2590
2595
2600
2605
2610
2615
2620
2625
2630
2635
2640
2645
2650
2655
2660
2665
2670
2675
2680
2685
2690
2695
2700
2705
2710
2715
2720
2725
2730
2735
2740
2745
2750
2755
2760
2765
2770
2775
2780
2785
2790
2795
2800
2805
2810
2815
2820
2825
2830
2835
2840
2845
2850
2855
2860
2865
2870
2875
2880
2885
2890
2895
2900
2905
2910
2915
2920
2925
2930
2935
2940
2945
2950
2955
2960
2965
2970
2975
2980
2985
2990
2995
3000
3005
3010
3015
3020
3025
3030
3035
3040
3045
3050
3055
3060
3065
3070
3075
3080
3085
3090
3095
3100
3105
3110
3115
3120
3125
3130
3135
3140
3145
3150
3155
3160
3165
3170
3175
3180
3185
3190
3195
3200
3205
3210
3215
3220
3225
3230
3235
3240
3245
3250
3255
3260
3265
3270
3275
3280
3285
3290
3295
3300
3305
3310
3315
3320
3325
3330
3335
3340
3345
3350
3355
3360
3365
3370
3375
3380
3385
3390
3395
3400
3405
3410
3415
3420
3425
3430
3435
3440
3445
3450
3455
3460
3465
3470
3475
3480
3485
3490
3495
3500
3505
3510
3515
3520
3525
3530
3535
3540
3545
3550
3555
3560
3565
3570
3575
3580
3585
3590
3595
3600
3605
3610
3615
3620
3625
3630
3635
3640
3645
3650
3655
3660
3665
3670
3675
3680
3685
3690
3695
3700
3705
3710
3715
3720
3725
3730
3735
3740
3745
3750
3755
3760
3765
3770
3775
3780
3785
3790
3795
3800
3805
3810
3815
3820
3825
3830
3835
3840
3845
3850
3855
3860
3865
3870
3875
3880
3885
3890
3895
3900
3905
3910
3915
3920
3925
3930
3935
3940
3945
3950
3955
3960
3965
3970
3975
3980
3985
3990
3995
4000
4005
4010
4015
4020
4025
4030
4035
4040
4045
4050
4055
4060
4065
4070
4075
4080
4085
4090
4095
4100
4105
4110
4115
4120
4125
4130
4135
4140
4145
4150
4155
4160
4165
4170
4175
4180
4185
4190
4195
4200
4205
4210
4215
4220
4225
4230
4235
4240
4245
4250
4255
4260
4265
4270
4275
4280
4285
4290
4295
4300
4305
4310
4315
4320
4325
4330
4335
4340
4345
4350
4355
4360
4365
4370
4375
4380
4385
4390
4395
4400
4405
4410
4415
4420
4425
4430
4435
4440
4445
4450
4455
4460
4465
4470
4475
4480
4485
4490
4495
4500
4505
4510
4515
4520
4525
4530
4535
4540
4545
4550
4555
4560
4565
4570
4575
4580
4585
4590
4595
4600
4605
4610
4615
4620
4625
4630
4635
4640
4645
4650
4655
4660
4665
4670
4675
4680
4685
4690
4695
4700
4705
4710
4715
4720
4725
4730
4735
4740
4745
4750
4755
4760
4765
4770
4775
4780
4785
4790
4795
4800
4805
4810
4815
4820
4825
4830
4835
4840
4845
4850
4855
4860
4865
4870
4875
4880
4885
4890
4895
4900
4905
4910
4915
4920
4925
4930
4935
4940
4945
4950
4955
4960
4965
4970
4975
4980
4985
4990
4995
5000
5005
5010
5015
5020
5025
5030
5035
5040
5045
5050
5055
5060
5065
5070
5075
5080
5085
5090
5095
5100
5105
5110
5115
5120
5125
5130
5135
5140
5145
5150
5155
5160
5165
5170
5175
5180
5185
5190
5195
5200
5205
5210
5215
5220
5225
5230
5235
5240
5245
5250
5255
5260
5265
5270
5275
5280
5285
5290
5295
5300
5305
5310
5315
5320
5325
5330
5335
5340
5345
5350
5355
5360
5365
5370
5375
5380
5385
5390
5395
5400
5405
5410
5415
5420
5425
5430
5435
5440
5445
5450
5455
5460
5465
5470
5475
5480
5485
5490
5495
5500
5505
5510
5515
5520
5525
5530
5535
5540
5545
5550
5555
5560
5565
5570
5575
5580
5585
5590
5595
5600
5605
5610
5615
5620
5625
5630
5635
5640
5645
5650
5655
5660
5665
5670
5675
5680
5685
5690
5695
5700
5705
5710
5715
5720
5725
5730
5735
5740
5745
5750
5755
5760
5765
5770
5775
5780
5785
5790
5795
5800
5805
5810
5815
5820
5825
5830
5835
5840
5845
5850
5855
5860
5865
5870
5875
5880
5885
5890
5895
5900
5905
5910
5915
5920
5925
5930
5935
5940
5945
5950
5955
5960
5965
5970
5975
5980
5985
5990
5995
6000
6005
6010
6015
6020
6025
6030
6035
6040
6045
6050
6055
6060
6065
6070
6075
6080
6085
6090
6095
6100
6105
6110
6115
6120
6125
6130
6135
6140
6145
6150
6155
6160
6165
6170
6175
6180
6185
6190
6195
6200
6205
6210
6215
6220
6225
6230
6235
6240
6245
6250
6255
6260
6265
6270
6275
6280
6285
6290
6295
6300
6305
6310
6315
6320
6325
6330
6335
6340
6345
6350
6355
6360
6365
6370
6375
6380
6385
6390
6395
6400
6405
6410
6415
6420
6425
6430
6435
6440
6445
6450
6455
6460
6465
6470
6475
6480
6485
6490
6495
6500
6505
6510
6515
6520
6525
6530
6535
6540
6545
6550
6555
6560
6565
6570
6575
6580
6585
6590
6595
6600
6605
6610
6615
6620
6625
6630
6635
6640
6645
6650
6655
6660
6665
6670
6675
6680
6685
6690
6695
6700
6705
6710
6715
6720
6725
6730
6735
6740
6745
6750
6755
6760
6765
6770
6775
6780
6785
6790
6795
6800
6805
6810
6815
6820
6825
6830
6835
6840
6845
6850
6855
6860
6865
6870
6875
6880
6885
6890
6895
6900
6905
6910
6915
6920
6925
6930
6935
6940
6945
6950
6955
6960
6965
6970
6975
6980
6985
6990
6995
7000
7005
7010
7015
7020
7025
7030
7035
7040
7045
7050
7055
7060
7065
7070
7075
7080
7085
7090
7095
7100
7105
7110
7115
7120
7125
7130
7135
7140
7145
7150
7155
7160
7165
7170
7175
7180
7185
7190
7195
7200
7205
7210
7215
7220
7225
7230
7235
7240
7245
7250
7255
7260
7265
7270
7275
7280
7285
7290
7295
7300
7305
7310
7315
7320
7325
7330
7335
7340
7345
7350
7355
7360
7365
7370
7375
7380
7385
7390
7395
7400
7405
7410
7415
7420
7425
7430
7435
7440
7445
7450
7455
7460
7465
7470
7475
7480
7485
7490
7495
7500
7505
7510
7515
7520
7525
7530
7535
7540
7545
7550
7555
7560
7565
7570
7575
7580
7585
7590
7595
7600
7605
7610
7615
7620
7625
7630
7635
7640
7645
7650
7655
7660
7665
7670
7675
7680
7685
7690
7695
7700
7705
7710
7715
7720
7725
7730
7735
7740
7745
7750
7755
7760
7765
7770
7775
7780
7785
7790
7795
7800
7805
7810
7815
7820
7825
7830
7835
7840
7845
7850
7855
7860
7865
7870
7875
7880
7885
7890
7895
7900
7905
7910
7915
7920
7925
7930
7935
7940
7945
7950
7955
7960
7965
7970
7975
7980
7985
7990
7995
8000
8005
8010
8015
8020
8025
8030
8035
8040
8045
8050
8055
8060
8065
8070
8075
8080
8085
8090
8095
8100
8105
8110
8115
8120
8125
8130
8135
8140
8145
8150
8155
8160
8165
8170
8175
8180
8185
8190
8195
8200
8205
8210
8215
8220
8225
8230
8235
8240
8245
8250
8255
8260
8265
8270
8275
8280
8285
8290
8295
8300
8305
8310
8315
8320
8325
8330
8335
8340
8345
8350
8355
8360
8365
8370
8375
8380
8385
8390
8395
8400
8405
8410
8415
8420
8425
8430
8435
8440
8445
8450
8455
8460
8465
8470
8475
8480
8485
8490
8495
8500
8505
8510
8515
8520
8525
8530
8535
8540
8545
8550
8555
8560
8565
8570
8575
8580
8585
8590
8595
8600
8605
8610
8615
8620
8625
8630
8635
8640
8645
8650
8655
8660
8665
8670
8675
8680
8685
8690
8695
8700
8705
8710
8715
8720
8725
8730
8735
8740
8745
8750
8755
8760
8765
8770
8775
8780
8785
8790
8795
8800
8805
8810
8815
8820
8825
8830
8835
8840
8845
8850
8855
8860
8865
8870
8875
8880
8885
8890
8895
8900
8905
8910
8915
8920
8925
8930
8935
8940
8945
8950
8955
8960
8965
8970
8975
8980
8985
8990
8995
9000
9005
9010
9015
9020
9025
9030
9035
9040
9045
9050
9055
9060
9065
9070
9075
9080
9085
9090
9095
9100
9105
9110
9115
9120
9125
9130
9135
9140
9145
9150
9155
9160
9165
9170
9175
9180
9185
9190
9195
9200
9205
9210
9215
9220
9225
9230
9235
9240
9245
9250
9255
9260
9265
9270
9275
9280
9285
9290
9295
9300
9305
9310
9315
9320
9325
9330
9335
9340
9345
9350
9355
9360
9365
9370
9375
9380
9385
9390
9395
9400
9405
9410
9415
9420
9425
9430
9435
9440
9445
9450
9455
9460
9465
9470
9475
9480
9485
9490
9495
9500
9505
9510
9515
9520
9525
9530
9535
9540
9545
9550
9555
9560
9565
9570
9575
9580
9585
9590
9595
9600
9605
9610
9615
9620
9625
9630
9635
9640
9645
9650
9655
9660
9665
9670
9675
9680
9685
9690
9695
9700
9705
9710
9715
9720
9725
9730
9735
9740
9745
9750
9755
9760
9765
9770
9775
9780
9785
9790
9795
9800
9805
9810
9815
9820
9825
9830
9835
9840
9845
9850
9855
9860
9865
9870
9875
9880
9885
9890
9895
9900
9905
9910
9915
9920
9925
9930
9935
9940
9945
9950
9955
9960
9965
9970
9975
9980
9985
9990
9995
10000
10005
10010
10015
10020
10025
10030
10035
10040
10045
10050
10055
10060
10065
10070
10075
10080
10085
10090
10095
10100
10105
10110
10115
10120
10125
10130
10135
10140
10145
10150
10155
10160
10165

EP 1 201 765 A2

| | | |
|----|---|------|
| 5 | gct tgg cca ttg aga ttt cgc atc ctg cat gaa att gcc ctt ggt gta Ala Trp Pro Leu Arg Phe Arg Ile Leu His Glu Ile Ala Leu Gly Val 120 125 130 | 620 |
| 10 | aat tac ctg cac aat atg act cct cct tta ctt cat cat gac ttg aag Asn Tyr Leu His Asn Met Thr Pro Pro Leu Leu His His Asp Leu Lys 135 140 145 | 668 |
| 15 | act cag aat atc tta ttg gac aat gaa ttt cat gtt aag att gca gat Thr Gln Asn Ile Leu Leu Asp Asn Glu Phe His Val Lys Ile Ala Asp 150 155 160 | 716 |
| 20 | ttt ggt tta tca aag tgg cgc atg atg tcc ctc tca cag tca cga agt Phe Gly Leu Ser Lys Trp Arg Met Met Ser Leu Ser Gln Ser Arg Ser 165 170 175 180 | 764 |
| 25 | agc aaa tct gca cca gaa gga ggg aca att atc tat atg cca cct gaa Ser Lys Ser Ala Pro Glu Gly Gly Thr Ile Ile Tyr Met Pro Pro Glu 185 190 195 | 812 |
| 30 | aac tat gaa cct gga caa aaa tca agg gcc agt atc aag cac gat ata Asn Tyr Glu Pro Gly Gln Lys Ser Arg Ala Ser Ile Lys His Asp Ile 200 205 210 | 860 |
| 35 | tat agc tat gca gtt atc aca tgg gaa gtg tta tcc aga aaa cag cct Tyr Ser Tyr Ala Val Ile Thr Trp Glu Val Leu Ser Arg Lys Gln Pro 215 220 225 | 908 |
| 40 | ttt gaa gat gtc acc aat cct ttg cag ata atg tat agt gtg tca caa Phe Glu Asp Val Thr Asn Pro Leu Gln Ile Met Tyr Ser Val Ser Gln 230 235 240 | 956 |
| 45 | gga cat cga cct gtt att aat gaa gaa agt ttg cca tat gat ata cct Gly His Arg Pro Val Ile Asn Glu Glu Ser Leu Pro Tyr Asp Ile Pro 245 250 255 260 | 1004 |
| 50 | cac cga gca cgt atg atc tct cta ata gaa agt gga tgg gca caa aat His Arg Ala Arg Met Ile Ser Leu Ile Glu Ser Gly Trp Ala Gln Asn 265 270 275 | 1052 |
| 55 | cca gat gaa aga cca tct ttc tta aaa tgt tta ata gaa ctt gaa cca Pro Asp Glu Arg Pro Ser Phe Leu Lys Cys Leu Ile Glu Leu Glu Pro 280 285 290 | 1100 |
| 60 | gtt ttg aga aca ttt gaa gag ata act ttt ctt gaa gct gtt att cag Val Leu Arg Thr Phe Glu Glu Ile Thr Phe Leu Glu Ala Val Ile Gln 295 300 305 | 1148 |
| 65 | cta aag aaa aca aag tta cag agt gtt tca agt gcc att cac cta tgt Leu Lys Lys Thr Lys Leu Gln Ser Val Ser Ala Ile His Leu Cys 310 315 320 | 1196 |
| 70 | gac aag aag aaa atg gaa tta tct ctg aac ata cct gta aat cat ggt Asp Lys Lys Lys Met Glu Leu Ser Leu Asn Ile Pro Val Asn His Gly 325 330 335 340 | 1244 |
| 75 | cca caa gag gaa tca tgt gga tcc tct cag ctc cat gaa aat agt ggt Pro Gln Glu Ser Cys Gly Ser Ser Gln Leu His Glu Asn Ser Gly 345 350 355 | 1292 |
| 80 | tct cct gaa act tca agg tcc ctg cca gct cct caa gac aat gat ttt Ser Pro Glu Thr Ser Arg Ser Leu Pro Ala Pro Gln Asp Asn Asp Phe 360 365 370 | 1340 |

| | | |
|----|--|------|
| | tta tct aga aaa gct caa gac tgt tat ttt atg aag ctg cat cac tgt | 1388 |
| | Leu Ser Arg Lys Ala Gln Asp Cys Tyr Phe Met Lys Leu His His Cys | |
| 5 | 375 380 385 | |
| | cct gga aat cac agt tgg gat agc acc att tct ggt tct caa agg gct | 1436 |
| | Pro Gly Asn His Ser Trp Asp Ser Thr Ile Ser Gly Ser Gln Arg Ala | |
| | 390 395 400 | |
| 10 | gca ttc tgt gat cac aag acc act cca tgc tct tca gca ata ata aat | 1484 |
| | Ala Phe Cys Asp His Lys Thr Thr Pro Cys Ser Ser Ala Ile Ile Asn | |
| | 405 410 415 420 | |
| 15 | cca ctc tca act gca gga aac tca gaa cgt ctg cag cct ggt ata gcc | 1532 |
| | Pro Leu Ser Thr Ala Gly Asn Ser Glu Arg Leu Gln Pro Gly Ile Ala | |
| | 425 430 435 | |
| | cag cag tgg atc cag agc aaa agg gaa gac att gtg aac caa atg aca | 1580 |
| | Gln Gln Trp Ile Gln Ser Lys Arg Glu Asp Ile Val Asn Gln Met Thr | |
| | 440 445 450 | |
| 20 | gaa gcc tgc ctt aac cag tcg cta gat gcc ctt ctg tcc agg gac ttg | 1628 |
| | Glu Ala Cys Leu Asn Gln Ser Leu Asp Ala Leu Leu Ser Arg Asp Leu | |
| | 455 460 465 | |
| 25 | atc atg aaa gag gac tat gaa ctt gtt agt acc aag cct aca agg acc | 1676 |
| | Ile Met Lys Glu Asp Tyr Glu Leu Val Ser Thr Lys Pro Thr Arg Thr | |
| | 470 475 480 | |
| | tca aaa gtc aga caa tta cta gac act act gac atc caa gga gaa gaa | 1724 |
| | Ser Lys Val Arg Gln Leu Leu Asp Thr Thr Asp Ile Gln Gly Glu Glu | |
| | 485 490 495 500 | |
| 30 | ttt gcc aaa gtt ata gta caa aaa ttg aaa gat aac aaa caa atg ggt | 1772 |
| | Phe Ala Lys Val Ile Val Gln Lys Leu Lys Asp Asn Lys Gln Met Gly | |
| | 505 510 515 | |
| 35 | ctt cag cct tac cog gaa ata ctt gtg gtt tct aga tca cca tct tta | 1820 |
| | Leu Gln Pro Tyr Pro Glu Ile Leu Val Val Ser Arg Ser Pro Ser Leu | |
| | 520 525 530 | |
| | aat tta ctt caa aat aaa agc atg taa gtgactgttt ttcaagaaga | 1867 |
| | Asn Leu Leu Gln Asn Lys Ser Met | |
| | 535 540 | |
| 40 | aatgtgtttc ataaaaggat atttatatct ctgttgcttt gactttttt atataaaatc | 1927 |
| | cgtgagtatt aaagctttat tgaaggttct ttgggtaaat attagtctcc ctccatgaca | 1987 |
| | ctgcagtatt ttttttaatt aataacaagta aaaagttgaa ttgggttcaa tttgctacat | 2047 |
| 45 | agtcaattt ttatgtctct tttgttaaca gaaaccactt ttaaaggata gtaattattc | 2107 |
| | ttgtttataa cagtgcctta aggtatgatg tatttctgat ggaagccatt ttcacattca | 2167 |
| | tgttcttcat ggattatgg ttacttgtct aagatgcaat ttgattttat gaagtatata | 2227 |
| 50 | ccctttaccc accagagaca gtacagaatc cctgccctaa aatcccaggc ttaattgccc | 2287 |
| | tacaaagggt tattaattta aaactccatt attaggatta catttaaag ttttatttat | 2347 |
| | gaattccctt taaaaatgat atttcaaagg taaaacaata caatataaag aaaaaaataa | 2407 |
| 55 | atatattaat accggcttcc tgtccccatt tttaacctca gcctccctaa ctgtcaccaa | 2467 |

caacccaagct aaataaaagtc aacagcctga tgtg

2501

<210> 2
 <211> 540
 <212> PRT
 <213> Homo sapiens

 10 <400> 2
 Met Asn Gly Glu Ala Ile Cys Ser Ala Leu Pro Thr Ile Pro Tyr His
 1 5 10 15
 Lys Leu Ala Asp Leu Arg Tyr Leu Ser Arg Gly Ala Ser Gly Thr Val
 20 25 30
 Ser Ser Ala Arg His Ala Asp Trp Arg Val Gln Val Ala Val Lys His
 35 40 45
 Leu His Ile His Thr Pro Leu Leu Asp Ser Glu Arg Lys Asp Val Leu
 50 55 60
 Arg Glu Ala Glu Ile Leu His Lys Ala Arg Phe Ser Tyr Ile Leu Pro
 65 70 75 80
 Ile Leu Gly Ile Cys Asn Glu Pro Glu Phe Leu Gly Ile Val Thr Glu
 85 90 95
 Tyr Met Pro Asn Gly Ser Leu Asn Glu Leu Leu His Arg Lys Thr Glu
 100 105 110
 Tyr Pro Asp Val Ala Trp Pro Leu Arg Phe Arg Ile Leu His Glu Ile
 115 120 125
 Ala Leu Gly Val Asn Tyr Leu His Asn Met Thr Pro Pro Leu Leu His
 130 135 140
 His Asp Leu Lys Thr Gln Asn Ile Leu Leu Asp Asn Glu Phe His Val
 145 150 155 160
 Lys Ile Ala Asp Phe Gly Leu Ser Lys Trp Arg Met Met Ser Leu Ser
 165 170 175
 Gln Ser Arg Ser Ser Lys Ser Ala Pro Glu Gly Gly Thr Ile Ile Tyr
 180 185 190
 Met Pro Pro Glu Asn Tyr Glu Pro Gly Gln Lys Ser Arg Ala Ser Ile
 195 200 205
 Lys His Asp Ile Tyr Ser Tyr Ala Val Ile Thr Trp Glu Val Leu Ser
 210 215 220
 Arg Lys Gln Pro Phe Glu Asp Val Thr Asn Pro Leu Gln Ile Met Tyr
 225 230 235 240
 Ser Val Ser Gln Gly His Arg Pro Val Ile Asn Glu Glu Ser Leu Pro
 245 250 255
 Tyr Asp Ile Pro His Arg Ala Arg Met Ile Ser Leu Ile Glu Ser Gly
 260 265 270
 Trp Ala Gln Asn Pro Asp Glu Arg Pro Ser Phe Leu Lys Cys Leu Ile
 275 280 285
 Glu Leu Glu Pro Val Leu Arg Thr Phe Glu Glu Ile Thr Phe Leu Glu
 290 295 300
 Ala Val Ile Gln Leu Lys Lys Thr Lys Leu Gln Ser Val Ser Ser Ala
 305 310 315 320
 Ile His Leu Cys Asp Lys Lys Lys Met Glu Leu Ser Leu Asn Ile Pro
 325 330 335
 Val Asn His Gly Pro Gln Glu Glu Ser Cys Gly Ser Ser Gln Leu His
 340 345 350
 Glu Asn Ser Gly Ser Pro Glu Thr Ser Arg Ser Leu Pro Ala Pro Gln
 355 360 365
 Asp Asn Asp Phe Leu Ser Arg Lys Ala Gln Asp Cys Tyr Phe Met Lys
 370 375 380
 Leu His His Cys Pro Gly Asn His Ser Trp Asp Ser Thr Ile Ser Gly
 385 390 395 400
 Ser Gln Arg Ala Ala Phe Cys Asp His Lys Thr Thr Pro Cys Ser Ser
 405 410 415
 Ala Ile Ile Asn Pro Leu Ser Thr Ala Gly Asn Ser Glu Arg Leu Gln
 420 425 430
 Pro Gly Ile Ala Gln Gln Trp Ile Gln Ser Lys Arg Glu Asp Ile Val

| | | |
|---------------------------------|---------------------|---------------------|
| 435 | 440 | 445 |
| Asn Gln Met Thr Glu Ala Cys | Leu Asn Gln Ser | Leu Asp Ala Leu Leu |
| 450 | 455 | 460 |
| Ser Arg Asp Leu Ile Met Lys | Glu Asp Tyr Glu | Leu Val Ser Thr Lys |
| 465 | 470 | 475 |
| Pro Thr Arg Thr Ser Lys Val Arg | Gln Leu Leu Asp Thr | Thr Asp Ile |
| 485 | 490 | 495 |
| Gln Gly Glu Glu Phe Ala Lys Val | Ile Val Gln Lys Leu | Lys Asp Asn |
| 500 | 505 | 510 |
| Lys Gln Met Gly Leu Gln Pro Tyr | Pro Glu Ile Leu | Val Val Ser Arg |
| 515 | 520 | 525 |
| Ser Pro Ser Leu Asn Leu Leu | Gln Asn Lys Ser | Met |
| 530 | 535 | 540 |

SEQUENCE LISTING

<110> Axxima Pharmaceuticals AG
 <120> CELLULAR KINASES INVOLVED IN CYTOMEGALOVIRUS INFECTION
 AND THEIR INHIBITION
 <130> U50062
 <140> ·
 <141>
 <160> 2
 <170> PatentIn Ver. 2.1
 <210> 1
 <211> 2617
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> CDS
 <222> (1)..(2016)
 <400> 1
 atg caa cca gac atg tcc ttg aat gtc att aag atg aaa tcc agt gac 48
 Met Gln Pro Asp Met Ser Leu Asn Val Ile Lys Met Lys Ser Ser Asp
 1 5 10 15
 ttc ctg gag agt gca gaa ctg gac agc gga ggc ttt ggg aag gtg tct 96
 Phe Leu Glu Ser Ala Glu Leu Asp Ser Gly Gly Phe Gly Lys Val Ser
 20 25 30
 ctg tgt ttc cac aga acc cag gga ctc atg atc atg aaa aca gtg tac 144
 Leu Cys Phe His Arg Thr Gln Gly Leu Met Ile Met Lys Thr Val Tyr
 35 40 45
 aag ggg ccc aac tgc att gag cac aac gag gcc ctc ttg gag gag gcg 192
 Lys Gly Pro Asn Cys Ile Glu His Asn Glu Ala Leu Leu Glu Glu Ala
 50 55 60
 aag atg atg aac aga ctg aga cac agc cgg gtg gtg aag ctc ctg ggc 240
 Lys Met Met Asn Arg Leu Arg His Ser Arg Val Val Lys Leu Leu Gly
 65 70 75 80
 gtc atc ata gag gaa ggg aag tac tcc ctg gtg atg gag tac atg gag 288
 Val Ile Ile Glu Glu Gly Lys Tyr Ser Leu Val Met Glu Tyr Met Glu
 85 90 95

| | | |
|----|---|------|
| | aag ggc aac ctg atg cac gtg ctg aaa gcc gag atg agt act ccg ctt | 336 |
| 5 | Lys Gly Asn Leu Met His Val Leu Lys Ala Glu Met Ser Thr Pro Leu | |
| | 100 105 110 | |
| | tct gta aaa gga agg ata att ttg gaa atc att gaa gga atg tgc tac | 384 |
| | Ser Val Lys Gly Arg Ile Ile Leu Glu Ile Ile Glu Gly Met Cys Tyr | |
| | 115 120 125 | |
| 10 | tta cat gga aaa ggc gtg ata cac aag gac ctg aag cct gaa aat atc | 432 |
| | Leu His Gly Lys Gly Val Ile His Lys Asp Leu Lys Pro Glu Asn Ile | |
| | 130 135 140 | |
| 15 | ctt gtt gat aat gac ttc cac att aag atc gca gac ctc ggc ctt gcc | 480 |
| | Leu Val Asp Asn Asp Phe His Ile Lys Ile Ala Asp Leu Gly Leu Ala | |
| | 145 150 155 160 | |
| | tcc ttt aag atg tgg agc aaa ctg aat aat gaa gag cac aat gag ctg | 528 |
| | Ser Phe Lys Met Trp Ser Lys Leu Asn Asn Glu Glu His Asn Glu Leu | |
| | 165 170 175 | |
| 20 | agg gaa gtg gac ggc acc gct aag aag aat ggc ggc acc ctc tac tac | 576 |
| | Arg Glu Val Asp Gly Thr Ala Lys Lys Asn Gly Gly Thr Leu Tyr Tyr | |
| | 180 185 190 | |
| 25 | atg gcg ccc gag cac ctg aat gac gtc aac gca aag ccc aca gag aag | 624 |
| | Met Ala Pro Glu His Leu Asn Asp Val Asn Ala Lys Pro Thr Glu Lys | |
| | 195 200 205 | |
| | tcg gat gtg tac agc ttt gct gta gta ctc tgg gcg ata ttt gca aat | 672 |
| | Ser Asp Val Tyr Ser Phe Ala Val Val Leu Trp Ala Ile Phe Ala Asn | |
| | 210 215 220 | |
| 30 | aag gag cca tat gaa aat gct atc tgt gag cag cag ttg ata atg tgc | 720 |
| | Lys Glu Pro Tyr Glu Asn Ala Ile Cys Glu Gln Gln Leu Ile Met Cys | |
| | 225 230 235 240 | |
| 35 | ata aaa tct ggg aac agg cca gat gtg gat gac atc act gag tac tgc | 768 |
| | Ile Lys Ser Gly Asn Arg Pro Asp Val Asp Asp Ile Thr Glu Tyr Cys | |
| | 245 250 255 | |
| | cca aga gaa att atc agt ctc atg aag ctc tgc tgg gaa gcg aat ccg | 816 |
| | Pro Arg Glu Ile Ile Ser Leu Met Lys Leu Cys Trp Glu Ala Asn Pro | |
| | 260 265 270 | |
| 40 | gaa gct cgg cca ttt cct ggc att gaa gaa aaa ttt agg cct ttt | 864 |
| | Glu Ala Arg Pro Thr Phe Pro Gly Ile Glu Glu Lys Phe Arg Pro Phe | |
| | 275 280 285 | |
| 45 | tat tta agt caa tta gaa gaa agt gta gaa gag gac gtg aag agt tta | 912 |
| | Tyr Leu Ser Gln Leu Glu Glu Ser Val Glu Glu Asp Val Lys Ser Leu | |
| | 290 295 300 | |
| | aag aaa gag tat tca aac gaa aat gca gtt gtg aag aga atg cag tct | 960 |
| | Lys Lys Glu Tyr Ser Asn Glu Asn Ala Val Val Lys Arg Met Gln Ser | |
| | 305 310 315 320 | |
| 50 | ctt caa ctt gat tgt gtg gca gta cct tca agc cgg tca aat tca gcc | 1008 |
| | Leu Gln Leu Asp Cys Val Ala Val Pro Ser Ser Arg Ser Asn Ser Ala | |
| | 325 330 335 | |
| 55 | aca gaa cag cct ggt tca ctg cac agt tcc cag gga ctt ggg atg ggt | 1056 |
| | Thr Glu Gln Pro Gly Ser Leu His Ser Ser Gln Gly Leu Gly Met Gly | |
| | 340 345 350 | |

| | | |
|----|---|------|
| | cct gtg gag gag tcc tgg ttt gct cct tcc ctg gag cac cca caa gaa Pro Val Glu Glu Ser Trp Phe Ala Pro Ser Leu Glu His Pro Gln Glu 355 360 365 | 1104 |
| 5 | gag aat gag ccc agc ctg cag agt aaa ctc caa gac gaa gcc aac tac Glu Asn Glu Pro Ser Leu Gln Ser Lys Leu Gln Asp Glu Ala Asn Tyr 370 375 380 | 1152 |
| 10 | cat ctt tat ggc agc cgc atg gac agg cag acg aaa cag cag ccc aga His Leu Tyr Gly Ser Arg Met Asp Arg Gln Thr Lys Gln Gln Pro Arg 385 390 395 400 | 1200 |
| 15 | cag aat gtg gct tac aac aga gag gag gaa agg aga cgc agg gtc tcc Gln Asn Val Ala Tyr Asn Arg Glu Glu Arg Arg Arg Arg Val Ser 405 410 415 | 1248 |
| 20 | cat gac cct ttt gca cag caa aga cct tac gag aat ttt cag aat aca His Asp Pro Phe Ala Gln Gln Arg Pro Tyr Glu Asn Phe Gln Asn Thr 420 425 430 | 1296 |
| 25 | gag gga aaa ggc act gtt tat tcc agt gca gcc agt cat ggt aat gca Glu Gly Lys Gly Thr Val Tyr Ser Ser Ala Ala Ser His Gly Asn Ala 435 440 445 | 1344 |
| 30 | gtg cac cag ccc tca ggg ctc acc agc caa cct caa gta ctg tat cag Val His Gln Pro Ser Gly Leu Thr Ser Gln Pro Gln Val Leu Tyr Gln 450 455 460 | 1392 |
| 35 | aac aat gga tta tat agc tca cat ggc ttt gga aca aga cca ctg gat Asn Asn Gly Leu Tyr Ser Ser His Gly Phe Gly Thr Arg Pro Leu Asp 465 470 475 480 | 1440 |
| 40 | cca gga aca gca ggt ccc aga gtt tgg tac agg cca att cca agt cat Pro Gly Thr Ala Gly Pro Arg Val Trp Tyr Arg Pro Ile Pro Ser His 485 490 495 | 1488 |
| 45 | atg cct agt ctg cat aat atc cca gtg cct gag acc aac tat cta gga Met Pro Ser Leu His Asn Ile Pro Val Pro Glu Thr Asn Tyr Leu Gly 500 505 510 | 1536 |
| 50 | aat aca ccc acc atg cca ttc agc tcc ttg cca cca aca gat gaa tct Asn Thr Pro Thr Met Pro Phe Ser Ser Leu Pro Pro Thr Asp Glu Ser 515 520 525 | 1584 |
| 55 | ata aaa tat acc ata tac aat agt act ggc att cag att gga gcc tac Ile Lys Tyr Thr Ile Tyr Asn Ser Thr Gly Ile Gln Ile Gly Ala Tyr 530 535 540 | 1632 |
| 60 | aat tat atg gag att ggt ggg acg agt tca tca cta cta gac agc aca Asn Tyr Met Glu Ile Gly Gly Thr Ser Ser Ser Leu Leu Asp Ser Thr 545 550 555 560 | 1680 |
| 65 | aat acg aac ttc aaa gaa gag cca gct gct aag tac caa gct atc ttt Asn Thr Asn Phe Lys Glu Glu Pro Ala Ala Lys Tyr Gln Ala Ile Phe 565 570 575 | 1728 |
| 70 | gat aat acc act agt ctg acg gat aaa cac ctg gac cca atc agg gaa Asp Asn Thr Thr Ser Leu Thr Asp Lys His Leu Asp Pro Ile Arg Glu 580 585 590 | 1776 |
| 75 | aat ctg gga aag cac tgg aaa aac tgt gcc cgt aaa ctg ggc ttc aca Asn Leu Gly Lys His Trp Lys Asn Cys Ala Arg Lys Leu Gly Phe Thr 595 600 605 | 1824 |

cag tct cag att gat gaa att gac cat gac tat gag cga gat gga ctg 1872
 Gln Ser Gln Ile Asp Glu Ile Asp His Asp Tyr Glu Arg Asp Gly Leu
 610 615 620

5
 aaa gaa aag gtt tac cag atg ctc caa aag tgg gtg atg agg gaa ggc 1920
 Lys Glu Lys Val Tyr Gln Met Leu Gln Lys Trp Val Met Arg Glu Gly
 625 630 635 640

10
 ata aag gga gcc acg gtg ggg aag ctg gcc cag gcg ctc cac cag tgt 1968
 Ile Lys Gly Ala Thr Val Gly Lys Leu Ala Gln Ala Leu His Gln Cys
 645 650 655

tcc agg atc gac ctt ctg agc agc ttg att tac gtc agc cag aac taa 2016
 Ser Arg Ile Asp Leu Leu Ser Ser Leu Ile Tyr Val Ser Gln Asn
 660 665 670

15
 ccctggatgg gctacggcag ctgaagtgga cgcctcaactt agcggataac cccagaaagt 2076
 tggctgcctc agagcattca gaattctgtc ctcactgata ggggtctgt gtctgcagaa 2136
 20
 atttngtttc ctgtacttca tagctggaga atggggaaag aaatctgcag caaaggggtc 2196
 tcactctgtt gccaggctgg tctcaaactt ctggactcaa gtgatcctcc cgccctggcc 2256
 ttccaaagtg ctgggatatac aggcaactgag ccactgcgc cagtcaacaa tccgntctga 2316
 25
 gaaaaagcgt a caggaaga cctcttaatg gcatagcacc aataaaaaaa tgactcctag 2376
 ttgtgtttgg aaagggagag aagagatgtc tgaggaaggt catgttctt cagcttatgg 2436
 catttcctag agttngttg aagcaagaag aaaaactcag agaatataaa atcaactttn 2496
 30
 aaaattgtgt gctctcttct tcacgttaggc tcctgttaaa aacaaagtgc agtcagattc 2556
 taagccctgt tcagagactt cgccgatcac agctgcagct caccgccaca tcacaggatc 2616
 C - 2617

35
 <210> 2
 <211> 671
 <212> PRT
 <213> Homo sapiens

<400> 2

40
 Met Gln Pro Asp Met Ser Leu Asn Val Ile Lys Met Lys Ser Ser Asp
 1 5 10 15
 Phe Leu Glu Ser Ala Glu Leu Asp Ser Gly Gly Phe Gly Lys Val Ser
 20 25 30
 Leu Cys Phe His Arg Thr Gln Gly Leu Met Ile Met Lys Thr Val Tyr
 35 40 45
 45
 Lys Gly Pro Asn Cys Ile Glu His Asn Glu Ala Leu Leu Glu Glu Ala
 50 55 60
 Lys Met Met Asn Arg Leu Arg His Ser Arg Val Val Lys Leu Leu Gly
 65 70 75 80
 Val Ile Ile Glu Glu Gly Lys Tyr Ser Leu Val Met Glu Tyr Met Glu
 85 90 95
 50
 Lys Gly Asn Leu Met His Val Leu Lys Ala Glu Met Ser Thr Pro Leu
 100 105 110
 Ser Val Lys Gly Arg Ile Ile Leu Glu Ile Ile Glu Gly Met Cys Tyr
 115 120 125
 Leu His Gly Lys Gly Val Ile His Lys Asp Leu Lys Pro Glu Asn Ile
 130 135 140
 55
 Leu Val Asp Asn Asp Phe His Ile Lys Ile Ala Asp Leu Gly Leu Ala
 145 150 155 160

SEQUENCE LISTING

5 <110> Axxima Pharmaceuticals AG
 10 <120> CELLULAR KINASES INVOLVED IN CYTOMEGALOVIRUS INFECTION
 15 <130> Y10256
 20 <140>
 <141>
 25 <160> 2
 30 <170> PatentIn Ver. 2.1
 35 <210> 1
 <211> 4596
 <212> DNA
 <213> Homo sapiens
 40 <220>
 <221> CDS
 <222> (233) .. (3076)
 45 <400> 1
 aagcggggga ctgtgccgtg tggAACGTGT agctgtttag aggtggactc tgttaccatt 60
 gagggatgttt ggaggatgag tatgtgtggc agaggcacac ataaacaggc agagaccctt 120
 tgccctgcc tttctcccc aacccaaggc tgacctgtgt tctcccaaggt ctgggattct 180
 50 aagtgacctg ctctgtgttt ggtctctctc aggatgagca caagcctggg ag atg gca 238
 Met Ala
 55 1
 56 gtg atg gaa atg gcc tgc cca ggt gcc cct ggc tca gca gtg ggg cag 286
 Val Met Glu Met Ala Cys Pro Gly Ala Pro Gly Ser Ala Val Gly Gln
 60 5 10 15
 65 cag aag gaa ctc ccc aag cca aag gag aag acg ccg cca ctg ggg aag 334
 Gln Lys Glu Leu Pro Lys Pro Lys Glu Lys Thr Pro Pro Leu Gly Lys
 70 20 25 30
 75 aaa cag agc tcc gtc tac aag ctt gag gcc gtg gag aag acg cct gtg 382
 Lys Gln Ser Ser Val Tyr Lys Leu Glu Ala Val Glu Lys Ser Pro Val
 80 35 40 45 50
 85 ttc tgc gga aag tgg gag atc ctg aat gac gtg att acc aag ggc aca 430
 Phe Cys Gly Lys Trp Glu Ile Leu Asn Asp Val Ile Thr Lys Gly Thr
 90 55 60 65
 95 gcc aag gaa ggc tcc gag gca ggg cca gct gcc atc tct atc atc gcc 478
 Ala Lys Glu Gly Ser Glu Ala Gly Pro Ala Ala Ile Ser Ile Ile Ala
 100 70 75 80
 105 cag gct gag tgt gag aat agc caa gag ttc agc ccc acc ttt tca gaa 526
 Gln Ala Glu Cys Glu Asn Ser Gln Glu Phe Ser Pro Thr Phe Ser Glu
 110 85 90 95
 115 cgc att ttc atc gct ggg tcc aaa cag tac agc cag tcc gag agt ctt 574
 Arg Ile Phe Ile Ala Gly Ser Lys Gln Tyr Ser Gln Ser Glu Ser Leu
 120 100 105 110

EP 1 201 765 A2

| | | |
|----|---|------|
| 5 | gat cag atc ccc aac aat gtg gcc cat gct aca gag ggc aaa atg gcc Asp Gln Ile Pro Asn Asn Val Ala His Ala Thr Glu Gly Lys Met Ala 115 120 125 130 | 622 |
| | cgt gtg tgt tgg aag gga aag cgt cgc agc aaa gcc cggt aag aaa cgg Arg Val Cys Trp Lys Gly Lys Arg Arg Ser Lys Ala Arg Lys Lys Arg 135 140 145 | 670 |
| 10 | aag aag aag agc tca aag tcc ctg gct cat gca gga gtg gcc ttg gcc Lys Lys Lys Ser Ser Lys Ser Leu Ala His Ala Gly Val Ala Leu Ala 150 155 160 | 718 |
| 15 | aaa ccc ctc ccc agg acc cct gag cag gag agc tgc acc atc cca gtg Lys Pro Leu Pro Arg Thr Pro Glu Gln Glu Ser Cys Thr Ile Pro Val 165 170 175 | 766 |
| | cag gag gat gag tct cca ctc ggc gca tat gtt aga aac acc ccc Gln Glu Asp Glu Ser Pro Leu Gly Ala Pro Tyr Val Arg Asn Thr Pro 180 185 190 | 814 |
| 20 | cag ttc acc aag cct ctg aag gaa cca ggc ctt ggg caa ctc tgt ttt Gln Phe Thr Lys Pro Leu Lys Glu Pro Gly Leu Gly Gln Leu Cys Phe 195 200 205 210 | 862 |
| 25 | aag cag ctt ggc gag ggc cta cgg ccc gct ctg cct cga tca gaa ctc Lys Gln Leu Gly Glu Leu Arg Pro Ala Leu Pro Arg Ser Glu Leu 215 220 225 | 910 |
| | cac aaa ctg atc agc ccc ttg caa tgt ctg aac cac gtg tgg aaa ctg His Lys Leu Ile Ser Pro Leu Gln Cys Leu Asn His Val Trp Lys Leu 230 235 240 | 958 |
| 30 | cac cac ccc cag gac gga ggc ccc ctg ccc ctg ccc acg cac ccc ttc His His Pro Gln Asp Gly Gly Pro Leu Pro Leu Pro Thr His Pro Phe 245 250 255 | 1006 |
| 35 | ccc tat agc aga ctg cct cat ccc ttc cca ttc cac cct ctc cag ccc Pro Tyr Ser Arg Leu Pro His Pro Phe Pro Phe His Pro Leu Gln Pro 260 265 270 | 1054 |
| | tgg aaa cct cac cct ctg gag tcc ttc ctg ggc aaa ctg gcc tgt gta Trp Lys Pro His Pro Leu Glu Ser Phe Leu Gly Lys Leu Ala Cys Val 275 280 285 290 | 1102 |
| 40 | gac agc cag aaa ccc ttg cct gac cca cac ctg agc aaa ctg gcc tgt Asp Ser Gln Lys Pro Leu Pro Asp Pro His Leu Ser Lys Leu Ala Cys 295 300 305 | 1150 |
| 45 | gta gac agt cca aag ccc ctg cct ggc cca cac ctg gag ccc agc tgc Val Asp Ser Pro Lys Pro Leu Pro Gly Pro His Leu Glu Pro Ser Cys 310 315 320 | 1198 |
| | ctg tct cgt ggt gcc cat gag aag ttt tct gtg gag gaa tac cta gtg Leu Ser Arg Gly Ala His Glu Lys Phe Ser Val Glu Glu Tyr Leu Val 325 330 335 | 1246 |
| 50 | cat gct ctg caa ggc agc gtg agc tca agc cag gcc cac agc ctg acc His Ala Leu Gln Gly Ser Val Ser Ser Gln Ala His Ser Leu Thr 340 345 350 | 1294 |
| 55 | agc ctg gcc aag acc tgg gca gca cgg ggc tcc aga tcc cgg gag ccc Ser Leu Ala Lys Thr Trp Ala Ala Arg Gly Ser Arg Ser Arg Glu Pro 355 360 365 370 | 1342 |

| | | |
|----|---|------|
| 5 | agc ccc aaa act gag gac aac gag ggt gtc ctg ctc act gag aaa ctc Ser Pro Lys Thr Glu Asp Asn Glu Gly Val Leu Leu Thr Glu Lys Leu 375 380 385 | 1390 |
| | aag cca gtg gat tat gag tac cga gaa gaa gtc cac tgg gcc acg cac Lys Pro Val Asp Tyr Glu Tyr Arg Glu Glu Val His Trp Ala Thr His 390 395 400 | 1438 |
| 10 | cag ctc cgc ctg ggc aga ggc tcc ttc gga gag gtg cac agg atg gag Gln Leu Arg Leu Gly Arg Gly Ser Phe Gly Glu Val His Arg Met Glu 405 410 415 | 1486 |
| 15 | gac aag cag act ggc ttc cag tgc gct gtc aaa aag gtg cgg ctg gaa Asp Lys Gln Thr Gly Phe Gln Cys Ala Val Lys Lys Val Arg Leu Glu 420 425 430 | 1534 |
| | gta ttt cgg gca gag gag ctg atg gca tgt gca gga ttg acc tca ccc Val Phe Arg Ala Glu Leu Met Ala Cys Ala Gly Leu Thr Ser Pro 435 440 445 450 | 1582 |
| 20 | aga att gtc cct ttg tat gga gct gtg aga gaa ggg cct tgg gtc aac Arg Ile Val Pro Leu Tyr Gly Ala Val Arg Glu Gly Pro Trp Val Asn 455 460 465 | 1630 |
| 25 | atc ttc atg gag ctg ctg gaa ggt ggc tcc ctg ggc cag ctg gtc aag Ile Phe Met Glu Leu Leu Gly Gly Ser Leu Gly Gln Leu Val Lys 470 475 480 | 1678 |
| | gag cag ggc tgt ctc cca gag gac cgg gcc ctg tac tac ctg ggc cag Glu Gln Gly Cys Leu Pro Glu Asp Arg Ala Leu Tyr Leu Gly Gln 485 490 495 | 1726 |
| 30 | gcc ctg gag ggt ctg gaa tac ctc cac tca cga agg att ctg cat ggg Ala Leu Glu Gly Leu Glu Tyr Leu His Ser Arg Arg Ile Leu His Gly 500 505 510 | 1774 |
| 35 | gac gtc aaa gct gac aac gtg ctc ctg tcc agc gat ggg agc cac gca Asp Val Lys Ala Asp Asn Val Leu Leu Ser Ser Asp Gly Ser His Ala 515 520 525 530 | 1822 |
| | gcc ctc tgt gac ttt ggc cat gct gtg tgt ctt caa cct gat ggc ctg Ala Leu Cys Asp Phe Gly His Ala Val Cys Leu Gln Pro Asp Gly Leu 535 540 545 | 1870 |
| 40 | gga aag tcc ttg ctc aca ggg gac tac atc cct ggc aca gag acc cac Gly Lys Ser Leu Leu Thr Gly Asp Tyr Ile Pro Gly Thr Glu Thr His 550 555 560 | 1918 |
| 45 | atg gct ccg gag gtg gtg ctg ggc agg agc tgc gac gcc aag gtg gat Met Ala Pro Glu Val Val Leu Gly Arg Ser Cys Asp Ala Lys Val Asp 565 570 575 | 1966 |
| | gtc tgg agc agc tgc tgt atg atg ctg cac atg ctc aac ggc tgc cac Val Trp Ser Ser Cys Cys Met Met Leu His Met Leu Asn Gly Cys His 580 585 590 | 2014 |
| 50 | ccc tgg act cag ttc ttc cga ggg ccg ctc tgc ctc aag att gcc agc Pro Trp Thr Gln Phe Phe Arg Gly Pro Leu Cys Leu Lys Ile Ala Ser 595 600 605 610 | 2062 |
| 55 | gag cct ccg cct gtg agg gag atc cca ccc tcc tgc gcc cct ctc aca Glu Pro Pro Pro Val Arg Glu Ile Pro Pro Ser Cys Ala Pro Leu Thr 615 620 625 | 2110 |

| | | |
|----|---|------|
| 5 | gcc cag gcc atc caa gag ggg ctg agg aaa gag ccc atc cac cgc gtg Ala Gln Ala Ile Gln Glu Gly Leu Arg Lys Glu Pro Ile His Arg Val 630 635 640 | 2158 |
| | tct gca gcg gag ctg gga ggg aag gtg aac cgg gca cta cag caa gtg Ser Ala Ala Glu Leu Gly Gly Lys Val Asn Arg Ala Leu Gln Gln Val 645 650 655 | 2206 |
| 10 | gga ggt ctg aag agc cct tgg agg gga gaa tat aaa gaa cca aga cat Gly Gly Leu Lys Ser Pro Trp Arg Gly Glu Tyr Lys Glu Pro Arg His 660 665 670 | 2254 |
| 15 | cca ccg cca aat caa gcc aat tac cac cag acc ctc cat gcc cag ccg Pro Pro Pro Asn Gln Ala Asn Tyr His Gln Thr Leu His Ala Gln Pro 675 680 685 690 | 2302 |
| | aga gag ctt tcg cca agg gcc cca ggg ccc cgg cca gct gag gag aca Arg Glu Leu Ser Pro Arg Ala Pro Gly Pro Arg Pro Ala Glu Glu Thr 695 700 705 | 2350 |
| 20 | aca ggc aga gcc cct aag ctc cag cct ctc cca cca gag ccc cca Thr Gly Arg Ala Pro Lys Leu Gln Pro Pro Leu Pro Pro Glu Pro Pro 710 715 720 | 2398 |
| 25 | gag cca aac aag tct cct ccc ttg act ttg agc aag gag gag tct ggg Glu Pro Asn Lys Ser Pro Pro Leu Thr Leu Ser Lys Glu Glu Ser Gly 725 730 735 | 2446 |
| | atg tgg gaa ccc tta cct ctg tcc tcc ctg gag cca gcc cct gcc aga Met Trp Glu Pro Leu Pro Ser Ser Leu Glu Pro Ala Pro Ala Arg 740 745 750 | 2494 |
| 30 | aac ccc agc tca cca gag cgg aaa gca acc gtc ccg gag cag gaa ctg Asn Pro Ser Ser Pro Glu Arg Lys Ala Thr Val Pro Glu Gln Glu Leu 755 760 765 770 | 2542 |
| 35 | cag cag ctg gaa ata gaa tta ttc ctc aac agc ctg tcc cag cca ttt Gln Gln Leu Glu Ile Glu Leu Phe Leu Asn Ser Leu Ser Gln Pro Phe 775 780 785 | 2590 |
| | tct ctg gag gag cag gag caa att ctc tgc tcc agc atc gac agc Ser Leu Glu Glu Gln Ile Leu Ser Cys Leu Ser Ile Asp Ser 790 795 800 | 2638 |
| 40 | ctc tcc ctg tgc gat gac agt gag aag aac cca tca aag gcc tct caa Leu Ser Leu Ser Asp Asp Ser Glu Lys Asn Pro Ser Lys Ala Ser Gln 805 810 815 | 2686 |
| 45 | agc tcg cgg gac acc ctg agc tca ggc gta cac tcc tgg agc agc cag Ser Ser Arg Asp Thr Leu Ser Ser Gly Val His Ser Trp Ser Ser Gln 820 825 830 | 2734 |
| | gcc gag gct cga agc tcc agc tgg aac atg gtg ctg gcc cgg ggg cgg Ala Glu Ala Arg Ser Ser Trp Asn Met Val Leu Ala Arg Gly Arg 835 840 845 850 | 2782 |
| 50 | ccc acc gac acc cca agc tat ttc aat ggt gtg aaa gtc caa ata cag Pro Thr Asp Thr Pro Ser Tyr Phe Asn Gly Val Lys Val Gln Ile Gln 855 860 865 | 2830 |
| 55 | tct ctt aat ggt gaa cac ctg cac atc cgg gag ttc cac cgg gtc aaa Ser Leu Asn Gly Glu His Leu His Ile Arg Glu Phe His Arg Val Lys 870 875 880 | 2878 |

| | | |
|----|---|----------------|
| 5 | gtg gga gac atc gcc act ggc atc agc agc cag atc cca gct gca gcc Val Gly Asp Ile Ala Thr Gly Ile Ser Ser Gln Ile Pro Ala Ala Ala 885 890 895 | 2926 |
| | ttc agc ttg gtc acc aaa gac ggg cag cct gtt cgc tac gac atg gag Phe Ser Leu Val Thr Lys Asp Gly Gln Pro Val Arg Tyr Asp Met Glu 900 905 910 | 2974 |
| 10 | gtg cca gac tcg ggc atc gac ctg cag tgc aca ctg gcc cct gat ggc Val Pro Asp Ser Gly Ile Asp Leu Gln Cys Thr Leu Ala Pro Asp Gly 915 920 925 930 | 3022 |
| 15 | agc ttc gcc tgg agc tgg agg gtc aag cat ggc cag ctg gag aac agg Ser Phe Ala Trp Ser Trp Arg Val Lys His Gly Gln Leu Glu Asn Arg 935 940 945 | 3070 |
| | ccc taa ccctgccctc caccgcggc tccacactgc cggaaagcag ctttcctgtct Pro | 3126 |
| 20 | cgggtcacga tgctgcctc aaaacacagg ctcagccgtt cccagggat tgccagcccc ccggctcaca gtggaaacca gggctcgca gcagcaaggt gggggcaagc agaatgcctc ccaggatttc acacctgagc cctgccccac cctgctgaaa aaacatccgc cacgtgaaga | 3186 3246 3306 |
| 25 | gacagaagga ggtatggcagg agttacctgg ggaaacaaaa cagggatctt tttctgcccc tgctccagtc gagttggcct gaccgcctt gatcagtgtac catttggcgg cagacagggg agagcagctt ccagcctggg tcagaagggg tggcgagcc cttcgcccc tcaccctcca | 3366 3426 3486 |
| 30 | ggctgctgtg agagtgtcaa gtgtgttaagg gcccaaactc aggttcagtgc cagaaccagg tcagcaggtt tgcccgcccc taggttaagg gggccctcta aacccttgc ctggcctcac ctggccagct caccctttt ggggttaggg gaaaagaatg cctgaccctg ggaaggctcc | 3546 3606 3666 |
| 35 | ctggtagaat acaccacact tttcagggtt ttgcaacaca ggtcctgagt tgacctctgg ttcagccaaag gaccaaagaa ggtgtgttaag tgaagtgggtt ctcagcccc agacatgtgc cccttgctg ctggctacca ctcttccccca gagcagcagg ccccgagccc cttcaggccc | 3726 3786 3846 |
| 40 | agcaactgccc cagactcgct ggcactcagt tccctcatct gtaaagggtga agggtgatgc agatatgcc tgacaggaac agtctgttgg tggacatgtat cagtgttaag gaaaggcagca gagagagacg tccggcgccc cagccccact atcagtgtcc agcgtgtgg ttccccagag | 3906 3966 4026 |
| 45 | cacagctcag catcacactg acactcaccc tgccctgcc ctggccagag ggtactgccg acggcacttt gcactctgtat gaccaaag cactttcatg gctccctct ggcaggcag ggcaggccag tgacactgtt ggagcatagc aagccaggag atgggtgaa gggacacagt | 4086 4146 4206 |
| 50 | ctttagctgt ccacatgtat gtgactcctc aaaccttcc cagatttctc taagaatagc acccttcc ccattgcccc agcttagcct cttctccag gggagctact caggactcac gtacgattaa atcagctgtt aatcgtcagg ggggtctgc tagcctcaac ctccctggggc | 4266 4326 4386 |
| 55 | aggggacgcc gagactccgtt gggagaagctt cattccaca tcttgccaaag acagcctttg | 4446 |

5 tccagctgtc cacattgagt cagactgctc ccggggagag agccccggcc cccacacat 4506
 aaagaactgc agccttggta ctgcagagtc tggttttag agaactctt gtaagcaata 4566
 aagtttgggg tgatgacaaa tgttaaaaaa 4596
 10 <210> 2
 <211> 947
 <212> PRT
 <213> Homo sapiens
 15 <400> 2
 Met Ala Val Met Glu Met Ala Cys Pro Gly Ala Pro Gly Ser Ala Val
 1 5 10 15
 Gly Gln Gln Lys Glu Leu Pro Lys Pro Lys Glu Lys Thr Pro Pro Leu
 20 25 30
 Gly Lys Lys Gln Ser Ser Val Tyr Lys Leu Glu Ala Val Glu Lys Ser
 35 40 45
 Pro Val Phe Cys Gly Lys Trp Glu Ile Leu Asn Asp Val Ile Thr Lys
 50 55 60
 Gly Thr Ala Lys Glu Gly Ser Glu Ala Gly Pro Ala Ala Ile Ser Ile
 65 70 75 80
 Ile Ala Gln Ala Glu Cys Glu Asn Ser Gln Glu Phe Ser Pro Thr Phe
 85 90 95
 Ser Glu Arg Ile Phe Ile Ala Gly Ser Lys Gln Tyr Ser Gln Ser Glu
 100 105 110
 Ser Leu Asp Gln Ile Pro Asn Asn Val Ala His Ala Thr Glu Gly Lys
 115 120 125
 Met Ala Arg Val Cys Trp Lys Gly Lys Arg Arg Ser Lys Ala Arg Lys
 130 135 140
 Lys Arg Lys Lys Ser Ser Lys Ser Leu Ala His Ala Gly Val Ala
 145 150 155 160
 Leu Ala Lys Pro Leu Pro Arg Thr Pro Glu Gln Glu Ser Cys Thr Ile
 165 170 175
 Pro Val Gln Glu Asp Glu Ser Pro Leu Gly Ala Pro Tyr Val Arg Asn
 180 185 190
 Thr Pro Gln Phe Thr Lys Pro Leu Lys Glu Pro Gly Leu Gly Gln Leu
 195 200 205
 Cys Phe Lys Gln Leu Gly Glu Gly Leu Arg Pro Ala Leu Pro Arg Ser
 210 215 220
 Glu Leu His Lys Leu Ile Ser Pro Leu Gln Cys Leu Asn His Val Trp
 225 230 235 240
 Lys Leu His His Pro Gln Asp Gly Gly Pro Leu Pro Leu Pro Thr His
 245 250 255
 Pro Phe Pro Tyr Ser Arg Leu Pro His Pro Phe Pro Phe His Pro Leu
 260 265 270
 Gln Pro Trp Lys Pro His Pro Leu Glu Ser Phe Leu Gly Lys Leu Ala
 275 280 285
 Cys Val Asp Ser Gln Lys Pro Leu Pro Asp Pro His Leu Ser Lys Leu
 290 295 300
 Ala Cys Val Asp Ser Pro Lys Pro Leu Pro Gly Pro His Leu Glu Pro
 305 310 315 320
 Ser Cys Leu Ser Arg Gly Ala His Glu Lys Phe Ser Val Glu Glu Tyr
 325 330 335
 Leu Val His Ala Leu Gln Gly Ser Val Ser Ser Ser Gln Ala His Ser
 340 345 350
 Leu Thr Ser Leu Ala Lys Thr Trp Ala Ala Arg Gly Ser Arg Ser Arg
 355 360 365
 Glu Pro Ser Pro Lys Thr Glu Asp Asn Glu Gly Val Leu Leu Thr Glu
 370 375 380
 Lys Leu Lys Pro Val Asp Tyr Glu Tyr Arg Glu Glu Val His Trp Ala
 385 390 395 400
 Thr His Gln Leu Arg Leu Gly Arg Gly Ser Phe Gly Glu Val His Arg

| | | | |
|----|---|-----|-----|
| | 405 | 410 | 415 |
| 5 | Met Glu Asp Lys Gln Thr Gly Phe Gln Cys Ala Val Lys Lys Val Arg | | |
| | 420 | 425 | 430 |
| | Leu Glu Val Phe Arg Ala Glu Glu Leu Met Ala Cys Ala Gly Leu Thr | | |
| | 435 | 440 | 445 |
| | Ser Pro Arg Ile Val Pro Leu Tyr Gly Ala Val Arg Glu Gly Pro Trp | | |
| | 450 | 455 | 460 |
| 10 | Val Asn Ile Phe Met Glu Leu Leu Glu Gly Ser Leu Gly Gln Leu | | |
| | 465 | 470 | 475 |
| | Val Lys Glu Gln Gly Cys Leu Pro Glu Asp Arg Ala Leu Tyr Tyr Leu | | |
| | 485 | 490 | 495 |
| | Gly Gln Ala Leu Glu Gly Leu Glu Tyr Leu His Ser Arg Arg Ile Leu | | |
| | 500 | 505 | 510 |
| 15 | His Gly Asp Val Lys Ala Asp Asn Val Leu Leu Ser Ser Asp Gly Ser | | |
| | 515 | 520 | 525 |
| | His Ala Ala Leu Cys Asp Phe Gly His Ala Val Cys Leu Gln Pro Asp | | |
| | 530 | 535 | 540 |
| | Gly Leu Gly Lys Ser Leu Leu Thr Gly Asp Tyr Ile Pro Gly Thr Glu | | |
| | 545 | 550 | 555 |
| 20 | Thr His Met Ala Pro Glu Val Val Leu Gly Arg Ser Cys Asp Ala Lys | | |
| | 565 | 570 | 575 |
| | Val Asp Val Trp Ser Ser Cys Cys Met Met Leu His Met Leu Asn Gly | | |
| | 580 | 585 | 590 |
| | Cys His Pro Trp Thr Gln Phe Phe Arg Gly Pro Leu Cys Leu Lys Ile | | |
| | 595 | 600 | 605 |
| 25 | Ala Ser Glu Pro Pro Pro Val Arg Glu Ile Pro Pro Ser Cys Ala Pro | | |
| | 610 | 615 | 620 |
| | Leu Thr Ala Gln Ala Ile Gln Glu Gly Leu Arg Lys Glu Pro Ile His | | |
| | 625 | 630 | 635 |
| | Arg Val Ser Ala Ala Glu Leu Gly Gly Lys Val Asn Arg Ala Leu Gln | | |
| | 645 | 650 | 655 |
| 30 | Gln Val Gly Gly Leu Lys Ser Pro Trp Arg Gly Glu Tyr Lys Glu Pro | | |
| | 660 | 665 | 670 |
| | Arg His Pro Pro Pro Asn Gln Ala Asn Tyr His Gln Thr Leu His Ala | | |
| | 675 | 680 | 685 |
| | Gln Pro Arg Glu Leu Ser Pro Arg Ala Pro Gly Pro Arg Pro Ala Glu | | |
| | 690 | 695 | 700 |
| 35 | Glu Thr Thr Gly Arg Ala Pro Lys Leu Gln Pro Pro Leu Pro Pro Glu | | |
| | 705 | 710 | 715 |
| | Pro Pro Glu Pro Asn Lys Ser Pro Pro Leu Thr Leu Ser Lys Glu Glu | | |
| | 725 | 730 | 735 |
| | Ser Gly Met Trp Glu Pro Leu Pro Leu Ser Ser Leu Glu Pro Ala Pro | | |
| | 740 | 745 | 750 |
| 40 | Ala Arg Asn Pro Ser Ser Pro Glu Arg Lys Ala Thr Val Pro Glu Gln | | |
| | 755 | 760 | 765 |
| | Glu Leu Gln Gln Leu Glu Ile Glu Leu Phe Leu Asn Ser Leu Ser Gln | | |
| | 770 | 775 | 780 |
| | Pro Phe Ser Leu Glu Glu Gln Glu Gln Ile Leu Ser Cys Leu Ser Ile | | |
| | 785 | 790 | 795 |
| 45 | Asp Ser Leu Ser Leu Ser Asp Asp Ser Glu Lys Asn Pro Ser Lys Ala | | |
| | 805 | 810 | 815 |
| | Ser Gln Ser Ser Arg Asp Thr Leu Ser Ser Gly Val His Ser Trp Ser | | |
| | 820 | 825 | 830 |
| | Ser Gln Ala Glu Ala Arg Ser Ser Ser Trp Asn Met Val Leu Ala Arg | | |
| | 835 | 840 | 845 |
| 50 | Gly Arg Pro Thr Asp Thr Pro Ser Tyr Phe Asn Gly Val Lys Val Gln | | |
| | 850 | 855 | 860 |
| | Ile Gln Ser Leu Asn Gly Glu His Leu His Ile Arg Glu Phe His Arg | | |
| | 865 | 870 | 875 |
| | Val Lys Val Gly Asp Ile Ala Thr Gly Ile Ser Ser Gln Ile Pro Ala | | |
| | 885 | 890 | 895 |
| 55 | Ala Ala Phe Ser Leu Val Thr Lys Asp Gly Gln Pro Val Arg Tyr Asp | | |
| | 900 | 905 | 910 |
| | Met Glu Val Pro Asp Ser Gly Ile Asp Leu Gln Cys Thr Leu Ala Pro | | |

915 920 925
 Asp Gly Ser Phe Ala Trp Ser Trp Arg Val Lys His Gly Gln Leu Glu
 930 935 940
 Asn Arg Pro
 945

SEQUENCE LISTING

10 <110> Axxima Pharmaceuticals AG
 <120> CELLULAR KINASES INVOLVED IN CYTOMEGALOVIRUS INFECTION
 AND THEIR INHIBITION
 15 <130> NM002756
 <140>
 <141>
 20 <160> 2
 <170> PatentIn Ver. 2.1
 <210> 1
 <211> 2030
 25 <212> DNA
 <213> Homo sapiens
 <220>
 <221> CDS
 <222> (338)..(1294)
 30 <400> 1
 tggctggcaa tggcattgct gacctcgagc cggggccacag tggggacctt tggagcacag 60
 cctacgatcc tggtgcaagg ccgggtggatg cagaggccag tccatataacc acccaggcct 120
 35 gcgaggagcg tggtccccac ccatccagcc catatgtgca agtgccttg acagagaggc 180
 tggtcataatc catggtgacc atttatgggc cacaacaggt ccccatctgc gcagtgaacc 240
 ctgtgctgag cacattgcag acgtgatctt gcttcgtctt gcagcactgt gcggggcagg 300
 40 aaaatccaag aggaagaagg atctacggat atcctgc atg tcc aag cca ccc gca 355
 Met Ser Lys Pro Pro Ala
 1 5
 ccc aac ccc aca ccc ccc cgg aac ctg gac tcc cgg acc ttc atc acc 403
 Pro Asn Pro Thr Pro Arg Asn Leu Asp Ser Arg Thr Phe Ile Thr
 45 10 15 20
 att gga gac aga aac ttt gag gtg gag gct gat gac ttg gtg acc atc 451
 Ile Gly Asp Arg Asn Phe Glu Val Glu Ala Asp Asp Leu Val Thr Ile
 25 30 35
 50 tca gaa ctg ggc cgt gga gcc tat ggg gtg gta gag aag gtg cgg cac 499
 Ser Glu Leu Gly Arg Gly Ala Tyr Gly Val Val Glu Lys Val Arg His
 40 45 50
 gcc cag agc ggc acc atc atg gcc gtg aag cgg atc cgg gcc acc gtg 547
 Ala Gln Ser Gly Thr Ile Met Ala Val Lys Arg Ile Arg Ala Thr Val
 55 60 65 70

| | | |
|----|--|------|
| | aac tca cag gag cag aag cgg ctg ctc atg gac ctg gac atc aac atg Asn Ser Gln Glu Gln Lys Arg Leu Leu Met Asp Leu Asp Ile Asn Met | 595 |
| 5 | 75 80 85 | |
| | cgc acg gtc gac tgt ttc tac act gtc acc ttc tac ggg gca cta ttc Arg Thr Val Asp Cys Phe Tyr Thr Val Thr Phe Tyr Gly Ala Leu Phe | 643 |
| | 90 95 100 | |
| 10 | aga gag gga gac gtg tgg atc tgc atg gag ctc atg gac aca tcc ttg Arg Glu Gly Asp Val Trp Ile Cys Met Glu Leu Met Asp Thr Ser Leu | 691 |
| | 105 110 115 | |
| 15 | gac aag ttc tac cgg aag gtg ctg gat aaa aac atg aca att cca gag Asp Lys Phe Tyr Arg Lys Val Leu Asp Lys Asn Met Thr Ile Pro Glu | 739 |
| | 120 125 130 | |
| | gac atc ctt ggg gag att gct gtg tct atc gtg cggtt ggc ctg gag cat Asp Ile Leu Glu Ile Ala Val Ser Ile Val Arg Ala Leu Glu His | 787 |
| | 135 140 145 150 | |
| 20 | ctg cac agc aag ctg tcg gtg atc cac aga gat gtg aag ccc tcc aat Leu His Ser Lys Leu Ser Val Ile His Arg Asp Val Lys Pro Ser Asn | 835 |
| | 155 160 165 | |
| 25 | gtc ctt atc aac aag gag ggc cat gtg aag atg tgt gac ttt ggc atc Val Leu Ile Asn Lys Glu Gly His Val Lys Met Cys Asp Phe Gly Ile | 883 |
| | 170 175 180 | |
| | agt ggc tac ttg gtg gac tct gtg gcc aag acg atg gat gcc ggc tgc Ser Gly Tyr Leu Val Asp Ser Val Ala Lys Thr Met Asp Ala Gly Cys | 931 |
| | 185 190 195 | |
| 30 | aag ccc tac atg gcc cct gag agg atc aac cca gag ctg aac cag aag Lys Pro Tyr Met Ala Pro Glu Arg Ile Asn Pro Glu Leu Asn Gln Lys | 979 |
| | 200 205 210 | |
| 35 | ggc tac aat gtc aag tcc gac gtc tgg agc ctg ggc atc acc atg att Gly Tyr Asn Val Lys Ser Asp Val Trp Ser Leu Gly Ile Thr Met Ile | 1027 |
| | 215 220 225 230 | |
| | gag atg gcc atc ctg cgg ttc cct tac gag tcc tgg ggg acc ccc ttc Glu Met Ala Ile Leu Arg Phe Pro Tyr Glu Ser Trp Gly Thr Pro Phe | 1075 |
| | 235 240 245 | |
| 40 | cag cag ctg aag cag gtg gtg gag gag ccc tcc ccc cag ctc cca gcc Gln Gln Leu Lys Gln Val Val Glu Glu Pro Ser Pro Gln Leu Pro Ala | 1123 |
| | 250 255 260 | |
| 45 | gac cgt ttc tcc ccc gag ttt gtg gac ttc act gct cag tgc ctg agg Asp Arg Phe Ser Pro Glu Phe Val Asp Phe Thr Ala Gln Cys Leu Arg | 1171 |
| | 265 270 275 | |
| | aag aac ccc gca gag cgt atg agc tac ctg gag ctg atg gag cac ccc Lys Asn Pro Ala Glu Arg Met Ser Tyr Leu Glu Leu Met Glu His Pro | 1219 |
| | 280 285 290 | |
| 50 | ttc ttc acc ttg cac aaa acc aag aag acg gac att gct gcc ttc gtg Phe Phe Thr Leu His Lys Thr Lys Thr Asp Ile Ala Ala Phe Val | 1267 |
| | 295 300 305 310 | |
| 55 | aag aag atc ctg gga gaa gac tca tag gggctggggcc tcggacccca Lys Lys Ile Leu Gly Glu Asp Ser | 1314 |
| | 315 | |

5 ctccggccct ccagagcccc acagccccat ctgcgggggc agtgctcacc cacaccataa 1374
 gctactgcca tcctggccca gggcatctgg gaggaaccga gggggctgct cccacctggc 1434
 tctgtggcga gccatttgtc ccaagtgcca aagaagcaga ccattgggc tccagccag 1494
 gcccctgtcg gccccaccag tgcctctccc tgctgctcct aggaccgtc tccagctgct 1554
 10 gagatcctgg actgaggggg cctggatgcc ccctgtggat gctgctgccc ctgcacagca 1614
 ggctgccagt gcctgggtgg atgggccacc gccttgccca gcctggatgc catccaagtt 1674
 gtatattttt ttaatctctc gactgaatgg actttgcaca ctggccca gggtgccac 1734
 15 acctctatcc cggctttggc gcggggtaca caagagggga tgagttgtgt gaataccca 1794
 agactcccat gagggagatg ccatgagccg cccaaaggcct tcccctggca ctggcaaaca 1854
 gggcctctgc ggagcacact ggctcaccca gtccctgccc ccaccgttat cggtgtcatt 1914
 20 caccttcgt gttttttta atttaccttc tgttgatttt ttctttgct ttatggttt 1974
 ggcttgggg tcttgcattgg ttggagctg atcgcttc ccccacccca tagggg 2030

25 <210> 2
 <211> 318
 <212> PRT
 <213> Homo sapiens

30 <400> 2
 Met Ser Lys Pro Pro Ala Pro Asn Pro Thr Pro Pro Arg Asn Leu Asp
 1 5 10 15
 Ser Arg Thr Phe Ile Thr Ile Gly Asp Arg Asn Phe Glu Val Glu Ala
 20 25 30
 Asp Asp Leu Val Thr Ile Ser Glu Leu Gly Arg Gly Ala Tyr Gly Val
 35 40 45
 Val Glu Lys Val Arg His Ala Gln Ser Gly Thr Ile Met Ala Val Lys
 50 55 60
 Arg Ile Arg Ala Thr Val Asn Ser Gln Glu Gln Lys Arg Leu Leu Met
 65 70 75 80
 Asp Leu Asp Ile Asn Met Arg Thr Val Asp Cys Phe Tyr Thr Val Thr
 85 90 95
 Phe Tyr Gly Ala Leu Phe Arg Glu Gly Asp Val Trp Ile Cys Met Glu
 100 105 110
 Leu Met Asp Thr Ser Leu Asp Lys Phe Tyr Arg Lys Val Leu Asp Lys
 115 120 125
 Asn Met Thr Ile Pro Glu Asp Ile Leu Gly Glu Ile Ala Val Ser Ile
 130 135 140
 Val Arg Ala Leu Glu His Leu His Ser Lys Leu Ser Val Ile His Arg
 145 150 155 160
 Asp Val Lys Pro Ser Asn Val Leu Ile Asn Lys Glu Gly His Val Lys
 165 170 175
 Met Cys Asp Phe Gly Ile Ser Gly Tyr Leu Val Asp Ser Val Ala Lys
 180 185 190
 Thr Met Asp Ala Gly Cys Lys Pro Tyr Met Ala Pro Glu Arg Ile Asn
 195 200 205
 Pro Glu Leu Asn Gln Lys Gly Tyr Asn Val Lys Ser Asp Val Trp Ser
 210 215 220
 Leu Gly Ile Thr Met Ile Glu Met Ala Ile Leu Arg Phe Pro Tyr Glu
 225 230 235 240
 Ser Trp Gly Thr Pro Phe Gln Gln Leu Lys Gln Val Val Glu Glu Pro
 245 250 255
 Ser Pro Gln Leu Pro Ala Asp Arg Phe Ser Pro Glu Phe Val Asp Phe

| | | |
|---------------------------------|---------------------------------|-------------|
| 260 | 265 | 270 |
| Thr Ala Gln Cys Leu Arg Lys Asn | Pro Ala Glu Arg Met | Ser Tyr Leu |
| 275 | 280 | 285 |
| Glu Leu Met Glu His Pro Phe Phe | Thr Leu His Lys Thr Lys Lys Thr | |
| 290 | 295 | 300 |
| Asp Ile Ala Ala Phe Val Lys Lys | Ile Leu Gly Glu Asp Ser | |
| 305 | 310 | 315 |

10 SEQUENCE LISTING

<110> Axxima Pharmaceuticals AG

<120> CELLULAR KINASES INVOLVED IN CYTOMEGALOVIRUS INFECTION
AND THEIR INHIBITION

<130> U 88666

<140>
<141>

20 <160> 2

<170> PatentIn Ver. 2.1

<210> 1
<211> 3745
<212> DNA
<213> Homo

| | | |
|----|--|--|
| 30 | <222> (188)..(2248) | |
| | <400> 1 | |
| | gaattcggca cgaggccatt gaatcccagt cctaacagaa gtactgcgaa tcttgtggcc 60 | |
| 35 | tcattctgaa caaaaggat tagagaagaa aaatctcttgcataaaggct tgaaagcaag 120 | |
| | ggcaggcaat cttgggtgtaatatttctgattttcca gaaatcaagc agaagattga 180 | |
| | gctgctg atg tca gtt aac tct gag aag tcg tcc tct tca gaa agg ccg 229 | |
| | Met Ser Val Asn Ser Glu Lys Ser Ser Ser Glu Arg Pro | |
| | 1 5 10 | |
| 40 | gag cct caa cag aaa gct cct tta gtt cct cct cct cca ccg cca cca 277 | |
| | Glu Pro Gln Gln Lys Ala Pro Leu Val Pro Pro Pro Pro Pro Pro Pro | |
| | 15 20 25 30 | |
| 45 | cc a cca cca ccg cca cct ttg cca gac ccc aca ccc ccg gag cca gag 325 | |
| | Pro Pro Pro Pro Pro Pro Leu Pro Asp Pro Thr Pro Pro Glu Pro Glu | |
| | 35 40 45 | |
| | gag gag atc ctg gga tca gat gat gag gag caa gag gac cct gcg gac 373 | |
| | Glu Glu Ile Leu Gly Ser Asp Asp Glu Gln Glu Asp Pro Ala Asp | |
| | 50 55 60 | |
| 50 | tac tgc aaa ggt gga tat cat cca gtg aaa att gga gac ctc ttc aat 421 | |
| | Tyr Cys Lys Gly Gly Tyr His Pro Val Lys Ile Gly Asp Leu Phe Asn | |
| | 65 70 75 | |
| 55 | ggc cgg tat cat gtt att aga aag ctt gga tgg ggg cac ttc tct act 469 | |
| | Gly Arg Tyr His Val Ile Arg Lys Leu Gly Trp Gly His Phe Ser Thr | |
| | 80 85 90 | |

| | | |
|----|---|------|
| 5 | gtc tgg ctg tgc tgg gat atg cag ggg aaa aga ttt gtt gca atg aaa Val Trp Leu Cys Trp Asp Met Gln Gly Lys Arg Phe Val Ala Met Lys 95 100 105 110 | 517 |
| | gtt gta aaa agt gcc cag cat tat acg gag aca gcc ttg gat gaa ata Val Val Lys Ser Ala Gln His Tyr Thr Glu Thr Ala Leu Asp Glu Ile 115 120 125 | 565 |
| 10 | aaa ttg ctc aaa tgt gtt cga gaa agt gat ccc agt gac cca aac aaa Lys Leu Leu Lys Cys Val Arg Glu Ser Asp Pro Ser Asp Pro Asn Lys 130 135 140 | 613 |
| 15 | gac atg gtg gtc cag ctc att gac gac ttc aag att tca ggc atg aat Asp Met Val Val Gln Leu Ile Asp Asp Phe Lys Ile Ser Gly Met Asn 145 150 155 | 661 |
| | ggg ata cat gtc tgc atg gtc ttc gaa gta ctt ggc cac cat ctc ctc Gly Ile His Val Cys Met Val Phe Glu Val Leu Gly His His Leu Leu 160 165 170 | 709 |
| 20 | aag tgg atc atc aaa tcc aac tat caa ggc ctc cca gta cgt tgt gtg Lys Trp Ile Ile Lys Ser Asn Tyr Gln Gly Leu Pro Val Arg Cys Val 175 180 185 190 | 757 |
| 25 | aag agt atc att cga cag gtc ctt caa ggg tta gat tac tta cac agt Lys Ser Ile Ile Arg Gln Val Leu Gln Gly Leu Asp Tyr Leu His Ser 195 200 205 | 805 |
| | aag tgc aag atc att cat act gac ata aag ccg gaa aat atc ttg atg Lys Cys Lys Ile Ile His Thr Asp Ile Lys Pro Glu Asn Ile Leu Met 210 215 220 | 853 |
| 30 | tgt gtg gat gat gca tat gtg aga aga atg gca gct gag cct gag tgg Cys Val Asp Asp Ala Tyr Val Arg Arg Met Ala Ala Glu Pro Glu Trp 225 230 235 | 901 |
| 35 | cag aaa gca ggt gct cct cct tca ggg tct gca gtg agt acg gct Gln Lys Ala Gly Ala Pro Pro Ser Gly Ser Ala Val Ser Thr Ala 240 245 250 | 949 |
| | cca cag cag aaa cct ata gga aaa ata tct aaa aac aaa aag aaa aaa Pro Gln Gln Lys Pro Ile Gly Lys Ile Ser Lys Asn Lys Lys Lys 255 260 265 270 | 997 |
| 40 | ctg aaa aag aaa cag aag agg cag gct gag tta ttg gag aag cgc ctg Leu Lys Lys Gln Lys Arg Gln Ala Glu Leu Leu Glu Lys Arg Leu 275 280 285 | 1045 |
| 45 | cag gag ata qaa gaa ttg gag cga gaa gct gaa agg aaa ata ata gaa Gln Glu Ile Glu Glu Leu Glu Arg Glu Ala Glu Arg Lys Ile Ile Glu 290 295 300 | 1093 |
| | gaa aac atc acc tca gct gca cct tcc aat gac cag gat ggc gaa tac Glu Asn Ile Thr Ser Ala Ala Pro Ser Asn Asp Gln Asp Gly Glu Tyr 305 310 315 | 1141 |
| 50 | tgc cca gag gtg aaa cta aaa aca aca gga tta gag gag gcg gct gag Cys Pro Glu Val Lys Leu Lys Thr Thr Gly Leu Glu Ala Ala Glu 320 325 330 | 1189 |
| 55 | gca gag act gca aag gac aat ggt gaa gct gag gac cag gaa gag aaa Ala Glu Thr Ala Lys Asp Asn Gly Glu Ala Glu Asp Gln Glu Glu Lys 335 340 345 350 | 1237 |

| | | |
|----|---|------|
| 5 | gaa gat gct gag aaa gaa aac att gaa aaa gat gaa gat gat gta gat Glu Asp Ala Glu Lys Glu Asn Ile Glu Lys Asp Glu Asp Asp Val Asp 355 360 365 | 1285 |
| | cag gaa ctt gcg aac ata gac cct acg tgg ata gaa tca cct aaa acc Gln Glu Leu Ala Asn Ile Asp Pro Thr Trp Ile Glu Ser Pro Lys Thr 370 375 380 | 1333 |
| 10 | aat ggc cat att gag aat ggc cca ttc tca ctg gag cag caa ctg gac Asn Gly His Ile Glu Asn Gly Pro Phe Ser Leu Glu Gln Gln Leu Asp 385 390 395 | 1381 |
| 15 | gat gaa gat gat gat gaa gaa gac tgc cca aat cct gag gaa tat aat Asp Glu Asp Asp Asp Glu Asp Cys Pro Asn Pro Glu Glu Tyr Asn 400 405 410 | 1429 |
| | ctt gat gag cca aat gca gaa agt gat tac aca tat agc agc tcc tat Leu Asp Glu Pro Asn Ala Glu Ser Asp Tyr Thr Tyr Ser Ser Ser Tyr 415 420 425 430 | 1477 |
| 20 | gaa caa ttc aat ggt gaa ttg cca aat gga cga cat aaa att ccc gag Glu Gln Phe Asn Gly Glu Leu Pro Asn Gly Arg His Lys Ile Pro Glu 435 440 445 | 1525 |
| 25 | tca cag ttc cca gag ttt tcc acc tcc ttg ttc tct gga tcc tta gaa Ser Gln Phe Pro Glu Phe Ser Thr Ser Leu Phe Ser Gly Ser Leu Glu 450 455 460 | 1573 |
| | cct gtg gcc tgc ggc tct gtg ctt tct gag gga tca cca ctt act gag Pro Val Ala Cys Gly Ser Val Leu Ser Glu Gly Ser Pro Leu Thr Glu 465 470 475 | 1621 |
| 30 | caa gag gag agc agt cca tcc cat gac aga agc aga acg gtt tca gcc Gln Glu Glu Ser Ser Pro Ser His Asp Arg Ser Arg Thr Val Ser Ala 480 485 490 | 1669 |
| 35 | tcc agt act ggg gat ttg cca aaa gca aaa acc cgg gca gct gac ttg Ser Ser Thr Gly Asp Leu Pro Lys Ala Lys Thr Arg Ala Ala Asp Leu 495 500 505 510 | 1717 |
| | ttg gtg aat ccc ctg gat ccg cgg aat cga gat aaa att aga gta aaa Leu Val Asn Pro Leu Asp Pro Arg Asn Arg Asp Lys Ile Arg Val Lys 515 520 525 | 1765 |
| 40 | att gct gac ctg gga aat gct tgt tgg gtg cat aaa cac ttc acg gaa Ile Ala Asp Leu Gly Asn Ala Cys Trp Val His Lys His Phe Thr Glu 530 535 540 | 1813 |
| 45 | gac atc cag acg cgt cag tac cgc tcc ata gag gtt tta ata gga gcg Asp Ile Gln Thr Arg Gln Tyr Arg Ser Ile Glu Val Leu Ile Gly Ala 545 550 555 | 1861 |
| | ggg tac agc acc cct gcg gac atc tgg agc acg gcg tgg atg gca ttt Gly Tyr Ser Thr Pro Ala Asp Ile Trp Ser Thr Ala Cys Met Ala Phe 560 565 570 | 1909 |
| 50 | gag ctg gca acg gga gat tat ttg ttt gaa cca cat tct ggg gaa gac Glu Leu Ala Thr Gly Asp Tyr Leu Phe Glu Pro His Ser Gly Glu Asp 575 580 585 590 | 1957 |
| 55 | tat tcc aga gac gaa gac cac ata gcc cac atc ata gag ctg cta ggc Tyr Ser Arg Asp Glu Asp His Ile Ala His Ile Ile Glu Leu Leu Gly 595 600 605 | 2005 |

| | | |
|----|---|-----------|
| 5 | agt att cca agg cac ttt gct cta tct gga aaa tat tct cg ^g gaa ttc Ser Ile Pro Arg His Phe Ala Leu Ser Gly Lys Tyr Ser Arg Glu Phe 610 615 620 | 2053 |
| | ttc aat cgc aga gga gaa ctg cga cac atc acc aag ctg aag ccc tgg Phe Asn Arg Arg Gly Glu Leu Arg His Ile Thr Lys Leu Lys Pro Trp 625 630 635 | 2101 |
| 10 | agc ctc ttt gat gta ctt gtg gaa aag tat ggc tgg ccc cat gaa gat Ser Leu Phe Asp Val Leu Val Glu Lys Tyr Gly Trp Pro His Glu Asp 640 645 650 | 2149 |
| 15 | gct gca cag ttt aca gat ttc ctg atc ccg atg tta gaa atg gtt cca Ala Ala Gln Phe Thr Asp Phe Leu Ile Pro Met Leu Glu Met Val Pro 655 660 665 670 | 2197 |
| | gaa aaa cga gcc tca gct ggc gaa tgt cgg cat cct tgg ttg aat tct Glu Lys Arg Ala Ser Ala Gly Glu Cys Arg His Pro Trp Leu Asn Ser 675 680 685 | 2245 |
| 20 | tag caaattctac caatattgca ttctgagcta gcaaatgttc ccagtacatt | 2298 |
| | ggacctaaac ggtgactctc attctttaac aggattacaa gtgagctg ^g ttcattcctca | 2358 |
| 25 | gacotttatt ttgctttgag gtactgttgt ttgacatttt gcttttgtg cactgtgatc ctggggaaagg gtagtctttt gtcttcagct aagtagttt ctgaccattt tcttctggaa | 2418 2478 |
| | acaataacat gtctctaagc attgtttctt gtgttgtgtg acattcaa ^a at gtcattttt | 2538 |
| 30 | tgaatgaaaa atacttccc ctttgtttt tggcagg ^{ttt} tgtaactatt tatgaagaaa | 2598 |
| | tatttagct gagtactata taatttacaa tcttaagaaa ttatcaagtt ggaaccaaga | 2658 |
| | aatagcaagg aaatgtacaa tttatcttc tggcaaagg ^g acatcattcc tgtattatag | 2718 |
| 35 | tgtatgtaaa tgcaccctgt aaatgttact ttccattaaa tatgggagg ^{gg} ggactcaa ^a | 2778 |
| | ttcagaaaag ctaccaagtc ttgagtgttt tgtagcctat gttgcatt ^g gcgacttt ^a | 2838 |
| | actgctccaa ggagttgtgc aaactttca ttccataaca gtctttcac attggatttt | 2898 |
| 40 | aaacaaagt ^g gctctgggtt ataagatgtc attctctata tggcacttta aaggaagaaa | 2958 |
| | agatatgttt ctcattctaa aatatgcatt ataatttagc agtcccattt gtgattttgc | 3018 |
| | atattttaa aagtactttt aaagaagagc aatttccctt taaaaatgtg atggctcagt | 3078 |
| 45 | accatgtcat gttgcctcct ctgggcgtg taagtt ^g tctacataga ttaaattgga | 3138 |
| | gaaacgtgtt aattgtgtgg aatgaaaaaa tacatataatt tttggaaaag catgatcatg | 3198 |
| | cttgtctaga acacaaggta tggtatatac aatttgcagt gcagtggca gaatacttct | 3258 |
| | cacagctcaa agataacagt gatcacattc attccatagg tagctttac ^g tgcgttaca | 3318 |
| 50 | acaaatttta ctagctttt cattgtcttt ccatgaaacg aagttgagaa aatgattttc | 3378 |
| | ccttgcagg ttgcacacag ttttgttat gcatttcctt aaaattaatt gttagactcca | 3438 |
| 55 | ggatacaaaac catagtaggc aatacaattt agaatgtaat atatagaggt atattagcct | 3498 |

ctttagaagt cagtggattg aatgtcttt tattttaat tttacattca ttaaggtgcc 3558
 5 tcgttttga ctttgtccat taacatttat ccatatgcct ttgcaataac tagattgtga 3618
 aaagctaaca agtgttgtaa caataatcca ttgtttgagg tgcttcagtg tgcgtttttttttttccag aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3678
 attaaagtgt tttggttttt tttttccag aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3738
 10 ttctgc 3745

<210> 2
 <211> 686
 <212> PRT
 15 <213> Homo sapiens

<400> 2
 Met Ser Val Asn Ser Glu Lys Ser Ser Ser Glu Arg Pro Glu Pro
 1 5 10 15
 Gln Gln Lys Ala Pro Leu Val Pro Pro Pro Pro Pro Pro Pro Pro
 20 25 30
 Pro Pro Pro Pro Leu Pro Asp Pro Thr Pro Pro Glu Pro Glu Glu
 35 40 45
 Ile Leu Gly Ser Asp Asp Glu Glu Gln Glu Asp Pro Ala Asp Tyr Cys
 50 55 60
 Lys Gly Gly Tyr His Pro Val Lys Ile Gly Asp Leu Phe Asn Gly Arg
 65 70 75 80
 Tyr His Val Ile Arg Lys Leu Gly Trp Gly His Phe Ser Thr Val Trp
 85 90 95
 Leu Cys Trp Asp Met Gln Gly Lys Arg Phe Val Ala Met Lys Val Val
 100 105 110
 Lys Ser Ala Gln His Tyr Thr Glu Thr Ala Leu Asp Glu Ile Lys Leu
 115 120 125
 Leu Lys Cys Val Arg Glu Ser Asp Pro Ser Asp Pro Asn Lys Asp Met
 130 135 140
 Val Val Gln Leu Ile Asp Asp Phe Lys Ile Ser Gly Met Asn Gly Ile
 145 150 155 160
 His Val Cys Met Val Phe Glu Val Leu Gly His His Leu Leu Lys Trp
 165 170 175
 Ile Ile Lys Ser Asn Tyr Gln Gly Leu Pro Val Arg Cys Val Lys Ser
 180 185 190
 Ile Ile Arg Gln Val Leu Gln Gly Leu Asp Tyr Leu His Ser Lys Cys
 195 200 205
 Lys Ile Ile His Thr Asp Ile Lys Pro Glu Asn Ile Leu Met Cys Val
 210 215 220
 Asp Asp Ala Tyr Val Arg Arg Met Ala Ala Glu Pro Glu Trp Gln Lys
 225 230 235 240
 Ala Gly Ala Pro Pro Ser Gly Ser Ala Val Ser Thr Ala Pro Gln
 245 250 255
 45 Gln Lys Pro Ile Gly Lys Ile Ser Lys Asn Lys Lys Lys Leu Lys
 260 265 270
 Lys Lys Gln Lys Arg Gln Ala Glu Leu Leu Glu Lys Arg Leu Gln Glu
 275 280 285
 Ile Glu Glu Leu Glu Arg Glu Ala Glu Arg Lys Ile Ile Glu Glu Asn
 290 295 300
 Ile Thr Ser Ala Ala Pro Ser Asn Asp Gln Asp Gly Glu Tyr Cys Pro
 305 310 315 320
 Glu Val Lys Leu Lys Thr Thr Gly Leu Glu Glu Ala Ala Glu Ala Glu
 325 330 335
 Thr Ala Lys Asp Asn Gly Glu Ala Glu Asp Gln Glu Glu Lys Glu Asp
 340 345 350
 Ala Glu Lys Glu Asn Ile Glu Lys Asp Glu Asp Asp Val Asp Gln Glu
 355 360 365
 55 Leu Ala Asn Ile Asp Pro Thr Trp Ile Glu Ser Pro Lys Thr Asn Gly

| | | | |
|----|---|-----|-----|
| 5 | 370 | 375 | 380 |
| | His Ile Glu Asn Gly Pro Phe Ser Leu Glu Gln Gln Leu Asp Asp Glu | | |
| | 385 | 390 | 395 |
| | Asp Asp Asp Glu Glu Asp Cys Pro Asn Pro Glu Glu Tyr Asn Leu Asp | | 400 |
| | 405 | 410 | 415 |
| | Glu Pro Asn Ala Glu Ser Asp Tyr Thr Ser Ser Ser Tyr Glu Gln | | |
| | 420 | 425 | 430 |
| 10 | Phe Asn Gly Glu Leu Pro Asn Gly Arg His Lys Ile Pro Glu Ser Gln | | |
| | 435 | 440 | 445 |
| | Phe Pro Glu Phe Ser Thr Ser Leu Phe Ser Gly Ser Leu Glu Pro Val | | |
| | 450 | 455 | 460 |
| | Ala Cys Gly Ser Val Leu Ser Glu Gly Ser Pro Leu Thr Glu Gln Glu | | |
| | 465 | 470 | 475 |
| 15 | Glu Ser Ser Pro Ser His Asp Arg Ser Arg Thr Val Ser Ala Ser Ser | | |
| | 485 | 490 | 495 |
| | Thr Gly Asp Leu Pro Lys Ala Lys Thr Arg Ala Ala Asp Leu Leu Val | | |
| | 500 | 505 | 510 |
| | Asn Pro Leu Asp Pro Arg Asn Arg Asp Lys Ile Arg Val Lys Ile Ala | | |
| 20 | 515 | 520 | 525 |
| | Asp Leu Gly Asn Ala Cys Trp Val His Lys His Phe Thr Glu Asp Ile | | |
| | 530 | 535 | 540 |
| | Gln Thr Arg Gln Tyr Arg Ser Ile Glu Val Leu Ile Gly Ala Gly Tyr | | |
| | 545 | 550 | 555 |
| | Ser Thr Pro Ala Asp Ile Trp Ser Thr Ala Cys Met Ala Phe Glu Leu | | |
| 25 | 565 | 570 | 575 |
| | Ala Thr Gly Asp Tyr Leu Phe Glu Pro His Ser Gly Glu Asp Tyr Ser | | |
| | 580 | 585 | 590 |
| | Arg Asp Glu Asp His Ile Ala His Ile Ile Glu Leu Leu Gly Ser Ile | | |
| | 595 | 600 | 605 |
| 30 | Pro Arg His Phe Ala Leu Ser Gly Lys Tyr Ser Arg Glu Phe Phe Asn | | |
| | 610 | 615 | 620 |
| | Arg Arg Gly Glu Leu Arg His Ile Thr Lys Leu Lys Pro Trp Ser Leu | | |
| | 625 | 630 | 635 |
| | Phe Asp Val Leu Val Glu Lys Tyr Gly Trp Pro His Glu Asp Ala Ala | | |
| | 645 | 650 | 655 |
| 35 | Gln Phe Thr Asp Phe Leu Ile Pro Met Leu Glu Met Val Pro Glu Lys | | |
| | 660 | 665 | 670 |
| | Arg Ala Ser Ala Gly Glu Cys Arg His Pro Trp Leu Asn Ser | | |
| | 675 | 680 | 685 |

40

Claims

1. Method for identifying compounds useful for treating and/or preventing Cytomegalovirus infection and/or associated diseases comprising:
 - a) contacting a test compound with one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2; and
 - b) detecting a change in activity of said cellular kinase.
2. Method for detecting Cytomegalovirus infection and/or associated diseases in an individual comprising:
 - a) providing a sample from said individual; and
 - b) detecting activity, in said sample, of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.
3. Method for detecting Cytomegalovirus infection and/or associated diseases in cells and/or cell lysates comprising:

a) providing a sample from said cells; and
 b) detecting activity, in said sample, of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

5 4. A monoclonal or polyclonal antibody that binds to a cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

10 5. Method for preventing and/or treating Cytomegalovirus infection and/or associated diseases in an individual by administering a pharmaceutically effective amount of an inhibitor to said individual, wherein said inhibitor inhibits at least partially the activity of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2, or wherein said inhibitor inhibits at least partially the production of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

15 6. Method for regulating the production of Cytomegalovirus in an individual by administering an individual a pharmaceutically effective amount of an inhibitor wherein said inhibitor inhibits at least partially the activity of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2, or wherein said inhibitor at least partially inhibits the production of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

20 7. Method for regulating the production of Cytomegalovirus in cells by administering the cells a pharmaceutically effective amount of an inhibitor wherein said inhibitor inhibits at least partially the activity of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2, or wherein said inhibitor at least partially inhibits the production of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2 in the cells.

25 8. Method according to claim 5, 6, or 7 wherein the inhibitor is a monoclonal or polyclonal antibody which binds to a cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

30 9. Method for preventing and/or treating Cytomegalovirus infection and/or associated diseases in an individual by administering a pharmaceutically effective amount of an activator to said individual, wherein said activator activates at least partially the activity of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2, or wherein said activator activates or stimulates at least partially the production of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

35 10. Method for regulating the production of Cytomegalovirus in an individual by administering an individual a pharmaceutically effective amount of an activator wherein said activator activates at least partially the activity of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2, or wherein said activator at least partially activates or stimulates the production of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

40 11. Method for regulating the production of Cytomegalovirus in cells by administering the cells a pharmaceutically effective amount of an activator wherein said activator activates at least partially the activity of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2, or wherein said activator at least partially activates or stimulates the production of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2 in the cells.

45 12. Oligonucleotide that binds to the DNA or RNA encoding a cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

50 13. Method for regulating the expression of at least one cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2 in an individual comprising the step of administering the individual a pharmaceutically effective amount of an inhibitor wherein said inhibitor inhibits at least partially the transcription of DNA or the translation of RNA encoding one of said cellular kinases.

55 14. Method for regulating the expression of at least one cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2 in cells comprising the step of administering the cells a pharmaceutically effective amount of an inhibitor wherein said inhibitor inhibits at least partially the transcription of DNA or the translation of RNA encoding one of said cellular kinases.

15. Method according to claim 5, 6, 7, 13, or 14 wherein the inhibitor is a oligonucleotide which binds to the DNA and/or RNA encoding a cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

5 16. Method for regulating the expression of at least one cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2 in an individual comprising the step of administering the individual a pharmaceutically effective amount of an activator wherein said activator activates at least partially the transcription of DNA or the translation of RNA encoding one of said cellular kinases.

10 17. Method for regulating the expression of at least one cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2 in cells comprising the step of administering the cells a pharmaceutically effective amount of an activator wherein said activator activates at least partially the transcription of DNA or the translation of RNA encoding one of said cellular kinases.

15 18. A solid support useful for detecting Cytomegalovirus infection of an individual comprising one or more immobilized oligonucleotides, wherein said oligonucleotide(s) is (are) capable of detecting activity of one or more cellular kinases selected from the group consisting of: RICK, RIP, NIK, MKK3, and SRPK-2.

20 19. A solid support useful for detecting Cytomegalovirus infection of cells comprising one or more immobilized oligonucleotides, wherein said oligonucleotide(s) is (are) capable of detecting activity of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

25 20. A solid support useful for screening compounds useful for treating and/or preventing Cytomegalovirus infection comprising one or more immobilized oligonucleotides, wherein said oligonucleotide(s) encode one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

21. A solid support useful for screening compounds useful for treating and/or preventing Cytomegalovirus infection comprising one or more immobilized cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

30 22. Composition useful to treat an individual afflicted with Cytomegalovirus and/or associated diseases comprising one or more inhibitors capable of inhibiting activity of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2 or capable of decreasing the expression of at least one cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

35 23. Composition useful to treat an individual afflicted with Cytomegalovirus and/or associated diseases comprising one or more activators capable of increasing activity of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2 or capable of increasing the expression of at least one cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

40 24. Composition useful to treat an individual afflicted with Cytomegalovirus comprising at least one compound selected from the group consisting of

6-(2,6-Dichlorophenyl)-8-methyl-2-(3-morpholin-4-yl-propylamino)-8H-pyrido[2,3-d]pyrimidin-7-one;
 8-methyl-6-phenyl-2-(pyridin-4-yl-amino)-8H-pyrido[2,3-d]pyrimidin-7-one;
 45 6-(2,6-Dichlorophenyl)-8-methyl-2-[3-(4-methylpiperazin-1-yl)-propylamino]-8H-pyrido[2,3-d]pyrimidin-7-one;
 (3-Bromophenyl)-(6,7-dimethoxyquinazolin-4-yl)-amine;
 (3-Bromophenyl)-(6,7-diethoxyquinazolin-4-yl)-amine;
 50 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one;
 5-Cloro-3-(1H-pyrrol-2-ylmethylene)-1,3-dihydroindol-2-one;
 4-Quinolin-4-ylmethylene-4H-isoquinoline-1,3-dione

and/or pharmaceutically acceptable salts of these compounds.

55 25. Composition according to any one of claims 17 - 19 further comprising pharmaceutically acceptable carriers, excipient, and/or diluents.

26. Use of the compounds selected from the group comprising:

6-(2,6-Dichlorophenyl)-8-methyl-2-(3-morpholin-4-yl-propylamino)-8H-pyrido[2,3-d]pyrimidin-7-one;
8-methyl-6-phenyl-2-(pyridin-4-yl-amino)-8H-pyrido[2,3-d]pyrimidin-7-one;
6-(2,6-Dichlorophenyl)-8-methyl-2-[3-(4-methylpiperazin-1-yl)-propylamino]-8H-pyrido[2,3-d]pyrimidin-7-one;
5 (3-Bromophenyl)-(6,7-dimethoxyquinazolin-4-yl)-amine;
(3-Bromophenyl)-(6,7-diethoxyquinazolin-4-yl)-amine and

pharmaceutically acceptable salts of these compounds as an inhibitor of the cellular kinase RICK.

10 27. Use of the compounds selected from the group comprising:

2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one;
5-Cloro-3-(1 H-pyrrol-2-ylmethylene)-1,3-dihydroindol-2-one;
4-Quinolin-4-ylmethylene-4H-isoquinoline-1,3-dione; and

15 pharmaceutically acceptable salts of these compounds as an inhibitor of the cellular kinase RIP.

20 28. Use of a compound according to claim 26 or 27 for the manufacture of a pharmaceutical composition for prophylaxis
and/or treatment of Cytomegalovirus infection and/or diseases associated therewith.

25

30

35

40

45

50

55

Figures

Fig. 1




Fig. 2

